Type I interferon-mediated tumor immunity and its role in immunotherapy

Immune checkpoint blockade (ICB) therapies have achieved remarkable clinical responses in patients with many different types of cancer; however, most patients who receive ICB monotherapy fail to achieve long-term responses, and some tumors become immunotherapy-resistant and even hyperprogressive. Ty...

Full description

Saved in:
Bibliographic Details
Published inCellular and molecular life sciences : CMLS Vol. 79; no. 3; p. 191
Main Authors Yu, Renren, Zhu, Bo, Chen, Degao
Format Journal Article
LanguageEnglish
Published Cham Springer International Publishing 01.03.2022
Springer Nature B.V
Subjects
Animals
Anticancer properties
Biochemistry
Biomedical and Life Sciences
Biomedicine
Cancer-Associated Fibroblasts - immunology
Cell Biology
Clinical trials
Combined Modality Therapy
Dendritic Cells - immunology
Endothelial Cells - immunology
Humans
Immune checkpoint
Immune Checkpoint Inhibitors - therapeutic use
Immune system
Immunity
Immunoregulation
Immunotherapy
Immunotherapy - methods
Interferon
Interferon Type I - biosynthesis
Interferon Type I - immunology
Killer Cells, Natural - immunology
Life Sciences
Lymphocytes, Tumor-Infiltrating - immunology
Macrophages - immunology
Mice
Models, Immunological
Myeloid-Derived Suppressor Cells - immunology
neoplasms
Neoplasms - immunology
Neoplasms - therapy
Neutrophils - immunology
Oncolytic Virotherapy
Patients
Review
Signal Transduction - immunology
synergism
Synergistic effect
T-Lymphocytes, Regulatory - immunology
Toll-Like Receptors - agonists
Tumor microenvironment
Tumor Microenvironment - immunology
Tumors
IFN-α
IFN-β
Tumor immunity
cGAS
Oncolytic virotherapy
STING
Radiation therapy
Online AccessGet full text
ISSN1420-682X
1420-9071
1420-9071
DOI10.1007/s00018-022-04219-z

Cover

Abstract Immune checkpoint blockade (ICB) therapies have achieved remarkable clinical responses in patients with many different types of cancer; however, most patients who receive ICB monotherapy fail to achieve long-term responses, and some tumors become immunotherapy-resistant and even hyperprogressive. Type I interferons (IFNs) have been demonstrated to inhibit tumor growth directly and indirectly by acting upon tumor and immune cells, respectively. Furthermore, accumulating evidence indicates that endo- and exogenously enhancing type I IFNs have a synergistic effect on anti-tumor immunity. Therefore, clinical trials studying new treatment strategies that combine type I IFN inducers with ICB are currently in progress. Here, we review the cellular sources of type I IFNs and their roles in the immune regulation of the tumor microenvironment. In addition, we highlight immunotherapies based on type I IFNs and combination therapy between type I IFN inducers and ICBs.
AbstractList Immune checkpoint blockade (ICB) therapies have achieved remarkable clinical responses in patients with many different types of cancer; however, most patients who receive ICB monotherapy fail to achieve long-term responses, and some tumors become immunotherapy-resistant and even hyperprogressive. Type I interferons (IFNs) have been demonstrated to inhibit tumor growth directly and indirectly by acting upon tumor and immune cells, respectively. Furthermore, accumulating evidence indicates that endo- and exogenously enhancing type I IFNs have a synergistic effect on anti-tumor immunity. Therefore, clinical trials studying new treatment strategies that combine type I IFN inducers with ICB are currently in progress. Here, we review the cellular sources of type I IFNs and their roles in the immune regulation of the tumor microenvironment. In addition, we highlight immunotherapies based on type I IFNs and combination therapy between type I IFN inducers and ICBs.
Immune checkpoint blockade (ICB) therapies have achieved remarkable clinical responses in patients with many different types of cancer; however, most patients who receive ICB monotherapy fail to achieve long-term responses, and some tumors become immunotherapy-resistant and even hyperprogressive. Type I interferons (IFNs) have been demonstrated to inhibit tumor growth directly and indirectly by acting upon tumor and immune cells, respectively. Furthermore, accumulating evidence indicates that endo- and exogenously enhancing type I IFNs have a synergistic effect on anti-tumor immunity. Therefore, clinical trials studying new treatment strategies that combine type I IFN inducers with ICB are currently in progress. Here, we review the cellular sources of type I IFNs and their roles in the immune regulation of the tumor microenvironment. In addition, we highlight immunotherapies based on type I IFNs and combination therapy between type I IFN inducers and ICBs.Immune checkpoint blockade (ICB) therapies have achieved remarkable clinical responses in patients with many different types of cancer; however, most patients who receive ICB monotherapy fail to achieve long-term responses, and some tumors become immunotherapy-resistant and even hyperprogressive. Type I interferons (IFNs) have been demonstrated to inhibit tumor growth directly and indirectly by acting upon tumor and immune cells, respectively. Furthermore, accumulating evidence indicates that endo- and exogenously enhancing type I IFNs have a synergistic effect on anti-tumor immunity. Therefore, clinical trials studying new treatment strategies that combine type I IFN inducers with ICB are currently in progress. Here, we review the cellular sources of type I IFNs and their roles in the immune regulation of the tumor microenvironment. In addition, we highlight immunotherapies based on type I IFNs and combination therapy between type I IFN inducers and ICBs.
ArticleNumber 191
Author Zhu, Bo
Yu, Renren
Chen, Degao
Author_xml – sequence: 1
  givenname: Renren
  surname: Yu
  fullname: Yu, Renren
  organization: Institute of Cancer, Xinqiao Hospital, Third Military Medical University, Department of Oncology, The First Affiliated Hospital of Wenzhou Medical University
– sequence: 2
  givenname: Bo
  surname: Zhu
  fullname: Zhu, Bo
  email: bo.zhu@tmmu.edu.cn
  organization: Institute of Cancer, Xinqiao Hospital, Third Military Medical University, Chongqing Key Laboratory of Immunotherapy, Xinqiao Hospital, Third Military Medical University
– sequence: 3
  givenname: Degao
  orcidid: 0000-0003-2744-427X
  surname: Chen
  fullname: Chen, Degao
  email: degaochen@tmmu.edu.cn
  organization: Institute of Cancer, Xinqiao Hospital, Third Military Medical University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/35292881$$D View this record in MEDLINE/PubMed
BookMark eNqNkUtP3TAQRq0KVB7tH-iiitRNNwG_EjsbpAq1gITEBiR2lq8zAaPEDrbTKvz6-pLb8lggVrY05xvNnNlDW847QOgLwQcEY3EYMcZElpjSEnNKmvLhA9olnOKywYJsbf61pNc7aC_Gu0xXktYf0Q6raEOlJLvo5HIeoTgrrEsQOgjelQO0VidoizQNPhR2GCZn01xo1xY2xSL4HjK_FHy6haDH-RPa7nQf4fPm3UdXv35eHp-W5xcnZ8c_zktTCZZKXTei7VqxIrQTFelMJWXT6Tx8bVoqjamBdkYawivREmiMZCuGia4l4HbFKNtHbOk7uVHPf3TfqzHYQYdZEazWWtSiRWUt6lGLesipoyU1Tqu8ngGXgn5Kem3Vy4qzt-rG_1ayoTxbzA2-bxoEfz9BTGqw0UDfawd-iorWXMqKcybeg2LMBedr9Nsr9M5PwWV_mWINoYxwnKmvz4f_P_W_I2ZALoAJPsYAnTI26WT9ehfbvy2Gvoq-y-bmBjHD7gbC09hvpP4CUWXReQ
CitedBy_id crossref_primary_10_4103_jcrt_jcrt_138_23
crossref_primary_10_3389_fimmu_2024_1470468
crossref_primary_10_3390_diagnostics13091635
crossref_primary_10_3390_cancers16030513
crossref_primary_10_1016_j_actbio_2023_01_023
crossref_primary_10_1007_s10048_024_00769_5
crossref_primary_10_1038_s41392_024_01937_7
crossref_primary_10_1111_cas_15844
crossref_primary_10_1200_PO_24_00179
crossref_primary_10_1111_jcmm_17536
crossref_primary_10_1007_s00251_025_01374_y
crossref_primary_10_3390_v15020283
crossref_primary_10_7759_cureus_50703
crossref_primary_10_1111_imr_13316
crossref_primary_10_1016_j_ccell_2023_12_005
crossref_primary_10_1016_j_antiviral_2023_105592
crossref_primary_10_1158_2326_6066_CIR_24_0026
crossref_primary_10_3389_fchbi_2025_1549003
crossref_primary_10_1186_s12951_024_02579_1
crossref_primary_10_1073_pnas_2403917121
crossref_primary_10_1038_s41598_024_76270_8
crossref_primary_10_1002_cbf_3954
crossref_primary_10_1016_j_mtbio_2023_100839
crossref_primary_10_1016_j_intimp_2024_112478
crossref_primary_10_1007_s11864_024_01211_6
crossref_primary_10_3389_fimmu_2022_1087620
crossref_primary_10_3389_fimmu_2024_1512353
crossref_primary_10_1158_2326_6066_CIR_24_0130
crossref_primary_10_1016_j_cpccr_2023_100255
crossref_primary_10_7554_eLife_95009
crossref_primary_10_1038_s41388_023_02791_7
crossref_primary_10_1038_s41392_023_01626_x
crossref_primary_10_3389_fonc_2024_1323070
crossref_primary_10_1021_acs_molpharmaceut_4c00841
crossref_primary_10_1177_15353702231179415
crossref_primary_10_1016_j_omton_2024_200815
crossref_primary_10_1158_0008_5472_CAN_23_0329
crossref_primary_10_1016_j_nantod_2023_102087
crossref_primary_10_1111_imm_13765
crossref_primary_10_1016_j_mcpro_2025_100919
crossref_primary_10_1016_j_ccell_2024_06_001
crossref_primary_10_1007_s10238_023_01015_2
crossref_primary_10_1016_j_canlet_2024_216988
crossref_primary_10_1186_s12951_024_02990_8
crossref_primary_10_3390_ijms24087359
crossref_primary_10_1021_acs_jmedchem_4c03207
crossref_primary_10_1136_jitc_2023_008386
crossref_primary_10_1016_j_molimm_2024_11_009
crossref_primary_10_1186_s12943_024_02107_7
crossref_primary_10_1002_mc_23753
crossref_primary_10_1007_s00262_023_03379_6
crossref_primary_10_1186_s12951_024_02903_9
crossref_primary_10_7717_peerj_18559
crossref_primary_10_3390_cancers16111999
crossref_primary_10_1038_s41598_024_57714_7
crossref_primary_10_1016_j_intimp_2023_110412
crossref_primary_10_1002_bkcs_12646
crossref_primary_10_3390_cells12091288
crossref_primary_10_3390_ijms25052830
crossref_primary_10_3390_pathogens12040607
crossref_primary_10_1038_s41388_024_03272_1
crossref_primary_10_1038_s41590_024_01960_4
crossref_primary_10_1002_cai2_70003
crossref_primary_10_1038_s41420_024_01997_2
crossref_primary_10_1186_s12967_023_04257_6
crossref_primary_10_3390_rheumato4040017
crossref_primary_10_1016_j_bbrep_2023_101573
crossref_primary_10_1136_jitc_2023_007625
crossref_primary_10_3390_pathogens14030229
crossref_primary_10_1016_j_intimp_2024_112571
crossref_primary_10_1155_2023_8776892
crossref_primary_10_3389_fmolb_2024_1409300
crossref_primary_10_1042_EBC20253006
crossref_primary_10_3389_fimmu_2025_1498323
crossref_primary_10_3390_pharmaceutics15020336
crossref_primary_10_1002_2211_5463_13671
crossref_primary_10_1016_j_imlet_2024_106938
crossref_primary_10_1016_j_trecan_2022_09_003
crossref_primary_10_3389_fcell_2023_1200466
crossref_primary_10_1038_s41423_024_01133_1
crossref_primary_10_1038_s41420_022_01256_2
crossref_primary_10_3390_ijms25147666
crossref_primary_10_3390_ijms252212456
crossref_primary_10_1186_s40364_024_00606_9
crossref_primary_10_1016_j_jconrel_2025_02_061
crossref_primary_10_1016_j_canlet_2023_216568
crossref_primary_10_3389_fimmu_2023_1104711
crossref_primary_10_21802_artm_2024_2_30_17
crossref_primary_10_3389_fonc_2023_1249524
crossref_primary_10_1007_s10014_023_00473_6
crossref_primary_10_3390_cells12192365
crossref_primary_10_1038_s41423_022_00953_3
crossref_primary_10_1038_s41392_024_01868_3
crossref_primary_10_2174_0109298673273303231208071403
crossref_primary_10_1016_j_bbcan_2023_188896
crossref_primary_10_1016_j_cellsig_2025_111647
crossref_primary_10_1016_j_cellimm_2023_104782
crossref_primary_10_3390_cancers15143666
crossref_primary_10_1002_cam4_70659
crossref_primary_10_1016_j_cell_2022_09_023
crossref_primary_10_1089_jir_2024_0107
crossref_primary_10_1136_jitc_2024_010534
crossref_primary_10_1016_j_phrs_2023_106996
crossref_primary_10_3389_fimmu_2024_1487372
crossref_primary_10_1186_s12964_023_01062_y
crossref_primary_10_1016_j_bbrc_2023_149209
crossref_primary_10_1371_journal_ppat_1011982
crossref_primary_10_3390_ijms24076736
crossref_primary_10_1136_jitc_2023_007766
crossref_primary_10_3389_fimmu_2022_1005045
crossref_primary_10_1016_j_canlet_2024_217410
crossref_primary_10_1016_j_mattod_2025_01_009
crossref_primary_10_1038_s41598_023_35834_w
crossref_primary_10_1002_advs_202400888
crossref_primary_10_3389_fimmu_2022_1070961
crossref_primary_10_1016_j_mtbio_2023_100926
crossref_primary_10_1016_j_molimm_2025_03_005
crossref_primary_10_3389_fimmu_2024_1419951
crossref_primary_10_1038_s41392_024_01765_9
crossref_primary_10_1021_acsapm_3c00548
crossref_primary_10_3390_genes15070959
crossref_primary_10_3389_fimmu_2023_1203929
crossref_primary_10_3389_fimmu_2023_1130060
crossref_primary_10_3389_fmicb_2023_1158777
crossref_primary_10_3389_fonc_2023_1064616
crossref_primary_10_3389_fimmu_2023_1190333
crossref_primary_10_3389_fimmu_2023_1258691
crossref_primary_10_1016_j_apsb_2024_07_024
crossref_primary_10_1016_j_immuni_2023_07_018
crossref_primary_10_1007_s13346_025_01798_9
crossref_primary_10_1186_s12951_023_02132_6
crossref_primary_10_1016_j_heliyon_2024_e24729
crossref_primary_10_1007_s00262_023_03603_3
crossref_primary_10_1089_jir_2024_0099
crossref_primary_10_3390_ijms242216048
crossref_primary_10_1016_j_apsb_2024_06_004
crossref_primary_10_1186_s12951_023_02170_0
crossref_primary_10_1158_2326_6066_CIR_23_1075
crossref_primary_10_1002_adfm_202307001
crossref_primary_10_1016_j_canlet_2024_217231
crossref_primary_10_3389_fphar_2024_1509482
crossref_primary_10_1016_j_canlet_2023_216483
crossref_primary_10_1038_s41392_024_02049_y
crossref_primary_10_1186_s13578_024_01231_7
crossref_primary_10_1016_j_jaci_2023_04_022
crossref_primary_10_3389_fimmu_2023_1272055
crossref_primary_10_1007_s12032_024_02320_w
crossref_primary_10_3389_fchbi_2024_1425571
crossref_primary_10_3389_fimmu_2023_1196829
Cites_doi 10.1158/2159-8290
10.1002/ijc.30159
10.1002/ijc.28551
10.1016/j.immuni.2018.09.016
10.1073/pnas.1016569108
10.1098/rspb.1957.0049
10.4161/onci.29179
10.1158/2159-8290.CD-18-0743
10.1007/s11060-020-03481-0
10.1111/j.1582-4934.2005.tb00353.x
10.1200/JCO.2010.28.9793
10.1016/j.celrep.2015.04.031
10.1158/0008-5472.CAN-12-3788
10.1002/adma.201803397
10.1200/JCO.2017.35.15_suppl.9510
10.1101/gad.4.10.1753
10.1172/JCI86892
10.1186/s40425-019-0568-2
10.1200/JCO.2011.35.0660
10.1080/2162402X.2020.1777624
10.1038/s41422-020-00395-4
10.1084/jem.20101159
10.1016/j.cell.2013.04.046
10.1158/2326-6074.TUMIMM17-B43
10.1038/nm1622
10.1200/JCO.2019.37.15_suppl.2507
10.1098/rspb.1957.0048
10.1073/pnas.58.3.1004
10.1038/cdd.2009.7
10.1038/nri3845
10.1038/s41467-021-22929-z
10.1016/j.ymthe.2020.11.002
10.1038/s41573-018-0011-2
10.1080/2162402X.2020.1796002
10.1016/j.celrep.2019.08.086
10.1016/j.celrep.2018.11.047
10.1016/j.semcancer.2017.12.007
10.1016/j.immuni.2019.03.025
10.1200/JCO.2014.58.3377
10.1038/nature07750
10.3389/fimmu.2018.00411
10.1158/1538-7445.AM2018-5554
10.1016/S0140-6736(20)32598-8
10.1038/s41568-020-0281-y
10.1002/adbi.201900237
10.1016/j.ccell.2020.12.022
10.1038/nature23470
10.1158/1538-7445.AM2017-CT026
10.1172/JCI121004
10.1016/j.addr.2021.05.013
10.1016/j.annonc.2021.08.1421
10.1016/j.ejca.2014.11.002
10.1158/0008-5472.CAN-13-2689
10.1016/j.cell.2017.01.017
10.1016/j.ccr.2013.12.004
10.1016/j.immuni.2020.05.013
10.1002/ijc.29444
10.1080/2162402X.2016.1214790
10.1016/j.immuni.2012.03.013
10.1016/j.ccell.2020.05.020
10.1186/s40425-019-0552-x
10.1038/s41422-019-0224-x
10.1186/s40425-016-0156-7
10.1016/bs.ircmb.2019.06.001
10.1111/j.0105-2896.2004.00204.x
10.1172/JCI61034
10.1158/1538-7445.AM2017-CT114
10.1016/j.addr.2008.12.008
10.1038/s41467-020-16602-0
10.1038/cddis.2016.90
10.1016/j.cell.2017.08.027
10.1158/2326-6066.CIR-17-0150
10.1002/jcp.27459
10.4049/jimmunol.178.12.7540
10.1158/1078-0432.CCR-20-1170
10.1200/jco.2014.32.15_suppl.6082
10.1056/NEJMoa1716435
10.1016/j.immuni.2014.10.017
10.1002/ijc.28957
10.1158/1078-0432.CCR-10-1114
10.1200/JCO.2021.39.15_suppl.2512
10.1038/nri1604
10.1016/j.annonc.2020.08.1207
10.1016/S1470-2045(19)30519-4
10.1172/JCI141614
10.1016/j.smim.2019.101299
10.1158/0008-5472.CAN-13-3356
10.1016/j.immuni.2018.03.017
10.1038/nm.3708
10.1016/j.ccell.2021.08.008
10.1158/2159-8290.CD-13-0458
10.1136/jitc-2020-001198
10.1038/s41416-020-01226-4
10.1126/scitranslmed.3000739
10.1038/gt.2013.31
10.1080/2162402X.2018.1532763
10.1002/ijc.29945
10.1038/cgt.2014.60
10.1038/ncomms15618
10.1101/gad.3.9.1362
10.1073/pnas.63.1.51
10.1038/nri3865
10.1172/jci.insight.120638
10.1093/annonc/mdz255
10.1158/0008-5472.CAN-11-0534
10.1136/jitc-2020-000940
10.1038/s41467-020-17011-z
10.1158/0008-5472.CAN-10-2820
10.1016/j.immuni.2014.10.019
10.1136/jitc-2020-002195
10.1084/jem.20200844
10.1126/scitranslmed.3008095
10.4049/jimmunol.1301419
10.15252/embj.2019104036
10.1136/ijgc-2019-001135
10.1038/nature06116
10.1016/S1470-2045(14)70189-5
10.1073/pnas.1512832112
10.1126/science.1229963
10.1186/s40425-019-0811-x
10.1111/ejh.12420
10.1038/s41586-019-1553-0
10.1172/JCI37223
10.1038/s41467-021-24867-2
10.1158/0008-5472.CAN-11-3468
10.1158/2159-8290.CD-18-0280
10.1200/JCO.2016.34.15_suppl.9568
10.1038/s41392-020-00377-3
10.1038/s41417-018-0059-5
10.1080/2162402X.2019.1659096
10.3389/fimmu.2016.00629
10.1038/nrc1628
10.1038/s41556-019-0298-1
10.1080/2162402X.2018.1526250
10.15252/embr.201439366
10.1016/j.cllc.2019.12.006
10.1126/scitranslmed.aao1641
10.1021/acsnano.9b04207
10.1200/JCO.2016.67.1529
10.1158/0008-5472.CAN-16-2165
10.1158/0008-5472.CAN-14-3499
10.1038/nrc.2016.14
10.1038/s41467-019-10970-y
10.1073/pnas.1621363114
10.1172/JCI127458
10.1126/scitranslmed.aan4488
10.1038/s42003-021-02004-5
10.1136/gutjnl-2020-323426
10.1038/s41392-021-00670-9
10.1038/s41467-021-22088-1
10.1158/1078-0432.CCR-10-2672
10.1200/JCO.2019.37.15_suppl.TPS9599
10.1093/annonc/mdy326
10.1038/s41556-020-0527-7
10.1038/nrd.2018.148
10.1200/JCO.2021.39.15_suppl.2549
10.1021/acsnano.0c02207
10.1172/JCI98047
10.1038/nature12640
ContentType Journal Article
Copyright The Author(s) 2022
2022. The Author(s).
Copyright Springer Nature B.V. Mar 2022
Copyright_xml – notice: The Author(s) 2022
– notice: 2022. The Author(s).
– notice: Copyright Springer Nature B.V. Mar 2022
DBID C6C
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7QL
7QP
7QR
7SS
7T5
7T7
7TK
7TM
7TO
7U7
7U9
7X2
7X7
7XB
88A
88E
8AO
8FD
8FE
8FH
8FI
8FJ
8FK
8G5
ABUWG
AEUYN
AFKRA
ATCPS
AZQEC
BBNVY
BENPR
BHPHI
C1K
CCPQU
DWQXO
FR3
FYUFA
GHDGH
GNUQQ
GUQSH
H94
HCIFZ
K9.
LK8
M0K
M0S
M1P
M2O
M7N
M7P
MBDVC
P64
PATMY
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
PYCSY
Q9U
RC3
7X8
7S9
L.6
5PM
ADTOC
UNPAY
DOI 10.1007/s00018-022-04219-z
DatabaseName Springer Nature OA Free Journals
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Bacteriology Abstracts (Microbiology B)
Calcium & Calcified Tissue Abstracts
Chemoreception Abstracts
Entomology Abstracts (Full archive)
Immunology Abstracts
Industrial and Applied Microbiology Abstracts (Microbiology A)
Neurosciences Abstracts
Nucleic Acids Abstracts
Oncogenes and Growth Factors Abstracts
Toxicology Abstracts
Virology and AIDS Abstracts
Agricultural Science Collection
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Biology Database (Alumni Edition)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
Technology Research Database
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Research Library
ProQuest Central (Alumni)
ProQuest One Sustainability
ProQuest Central UK/Ireland
Agricultural & Environmental Science Collection
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
Environmental Sciences and Pollution Management
ProQuest One Community College
ProQuest Central Korea
Engineering Research Database
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
ProQuest Research Library
AIDS and Cancer Research Abstracts
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
ProQuest Biological Science Collection
Agriculture Science Database
Health & Medical Collection (Alumni)
Medical Database
Research Library
Algology Mycology and Protozoology Abstracts (Microbiology C)
Biological Science Database
Research Library (Corporate)
Biotechnology and BioEngineering Abstracts
Environmental Science Database
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
Environmental Science Collection
ProQuest Central Basic
Genetics Abstracts
MEDLINE - Academic
AGRICOLA
AGRICOLA - Academic
PubMed Central (Full Participant titles)
Unpaywall for CDI: Periodical Content
Unpaywall
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Agricultural Science Database
Research Library Prep
ProQuest Central Student
Oncogenes and Growth Factors Abstracts
ProQuest Central Essentials
Nucleic Acids Abstracts
SciTech Premium Collection
ProQuest Central China
Environmental Sciences and Pollution Management
ProQuest One Applied & Life Sciences
ProQuest One Sustainability
Health Research Premium Collection
Natural Science Collection
Health & Medical Research Collection
Biological Science Collection
Chemoreception Abstracts
Industrial and Applied Microbiology Abstracts (Microbiology A)
ProQuest Central (New)
ProQuest Medical Library (Alumni)
Virology and AIDS Abstracts
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
Agricultural Science Collection
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
Neurosciences Abstracts
ProQuest Hospital Collection (Alumni)
Biotechnology and BioEngineering Abstracts
Environmental Science Collection
Entomology Abstracts
ProQuest Health & Medical Complete
ProQuest One Academic UKI Edition
Environmental Science Database
Engineering Research Database
ProQuest One Academic
Calcium & Calcified Tissue Abstracts
ProQuest One Academic (New)
Technology Research Database
ProQuest One Academic Middle East (New)
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
Research Library (Alumni Edition)
ProQuest Natural Science Collection
ProQuest Pharma Collection
ProQuest Biology Journals (Alumni Edition)
ProQuest Central
ProQuest Health & Medical Research Collection
Genetics Abstracts
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Bacteriology Abstracts (Microbiology B)
Algology Mycology and Protozoology Abstracts (Microbiology C)
Agricultural & Environmental Science Collection
AIDS and Cancer Research Abstracts
ProQuest Research Library
ProQuest Central Basic
Toxicology Abstracts
ProQuest SciTech Collection
ProQuest Medical Library
Immunology Abstracts
ProQuest Central (Alumni)
MEDLINE - Academic
AGRICOLA
AGRICOLA - Academic
DatabaseTitleList Agricultural Science Database

MEDLINE
AGRICOLA

CrossRef
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: C6C
  name: Springer Nature OA Free Journals
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: UNPAY
  name: Unpaywall
  url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/
  sourceTypes: Open Access Repository
– sequence: 5
  dbid: BENPR
  name: ProQuest Central
  url: http://www.proquest.com/pqcentral?accountid=15518
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Sciences (General)
Biology
EISSN 1420-9071
EndPage 191
ExternalDocumentID 10.1007/s00018-022-04219-z
PMC8924142
35292881
10_1007_s00018_022_04219_z
Genre Journal Article
Review
GrantInformation_xml – fundername: National Natural Science Foundation of China
  grantid: 82003018; 81925030
  funderid: http://dx.doi.org/10.13039/501100001809
– fundername: National Natural Science Foundation of China
  grantid: 81925030
– fundername: National Natural Science Foundation of China
  grantid: 82003018
– fundername: ;
  grantid: 82003018; 81925030
GroupedDBID ---
-56
-5G
-BR
-EM
-Y2
-~C
-~X
.55
.86
.GJ
.VR
06C
06D
0R~
0VY
199
1N0
2.D
203
29B
29~
2J2
2JN
2JY
2KG
2KM
2LR
2P1
2VQ
2~H
30V
36B
3O-
3SX
3V.
4.4
406
408
409
40D
40E
53G
5GY
5RE
5VS
67N
67Z
6NX
78A
7X2
7X7
7XC
88A
88E
8AO
8CJ
8FE
8FH
8FI
8FJ
8G5
8TC
8UJ
95-
95.
95~
96X
AAAVM
AABHQ
AAHBH
AAHNG
AAIAL
AAJKR
AAJSJ
AAKKN
AANXM
AANZL
AARHV
AARTL
AATVU
AAUYE
AAWCG
AAYIU
AAYQN
AAYTO
AAYZH
ABAKF
ABBBX
ABBXA
ABDZT
ABECU
ABEEZ
ABFTV
ABHLI
ABHQN
ABJNI
ABJOX
ABKCH
ABKTR
ABLJU
ABMNI
ABMOR
ABMQK
ABNWP
ABOCM
ABPLI
ABQBU
ABQSL
ABSXP
ABTEG
ABTHY
ABTKH
ABTMW
ABULA
ABUWG
ABWNU
ABXPI
ACACY
ACBXY
ACGFS
ACHSB
ACHVE
ACHXU
ACIWK
ACKNC
ACMDZ
ACMLO
ACNCT
ACOKC
ACOMO
ACPRK
ACULB
ACZOJ
ADBBV
ADHIR
ADIMF
ADINQ
ADKNI
ADKPE
ADRFC
ADTPH
ADURQ
ADYFF
ADYPR
ADZKW
AEBTG
AEFQL
AEGAL
AEGNC
AEJHL
AEJRE
AEKMD
AENEX
AEOHA
AEPYU
AESKC
AETLH
AEUYN
AEVLU
AEXYK
AFBBN
AFEXP
AFGCZ
AFGXO
AFKRA
AFLOW
AFQWF
AFRAH
AFWTZ
AFZKB
AGAYW
AGDGC
AGGDS
AGJBK
AGMZJ
AGQEE
AGQMX
AGRTI
AGWIL
AGWZB
AGYKE
AHAVH
AHBYD
AHKAY
AHMBA
AHSBF
AHYZX
AIAKS
AIIXL
AILAN
AITGF
AJBLW
AJRNO
AJZVZ
AKMHD
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ALWAN
AMKLP
AMXSW
AMYLF
AOCGG
APEBS
ARMRJ
ASPBG
ATCPS
AVWKF
AXYYD
AZFZN
AZQEC
B-.
BA0
BBNVY
BDATZ
BENPR
BGNMA
BHPHI
BPHCQ
BVXVI
C24
C6C
CAG
CCPQU
COF
CS3
CSCUP
D1J
D1K
DDRTE
DL5
DNIVK
DPUIP
DWQXO
EBD
EBLON
EBS
EIOEI
EJD
EMB
EMOBN
EN4
EPAXT
ESBYG
F5P
FEDTE
FERAY
FFXSO
FIGPU
FINBP
FNLPD
FRRFC
FSGXE
FWDCC
FYUFA
G-Y
G-Z
GGCAI
GGRSB
GJIRD
GNUQQ
GNWQR
GQ6
GQ7
GQ8
GUQSH
GXS
H13
HCIFZ
HF~
HG5
HG6
HMCUK
HMJXF
HQYDN
HRMNR
HVGLF
HZ~
IHE
IJ-
IKXTQ
ITM
IWAJR
IXC
IZIGR
IZQ
I~X
I~Z
J-C
J0Z
JBSCW
JCJTX
JZLTJ
K6-
KDC
KOV
KPH
LAS
LK5
LK8
LLZTM
M0K
M0L
M1P
M2O
M4Y
M7P
M7R
MA-
N2Q
N9A
NB0
NDZJH
NPVJJ
NQJWS
NU0
O9-
O93
O9G
O9I
O9J
OAM
P19
P2P
PATMY
PF0
PQQKQ
PROAC
PSQYO
PT5
PYCSY
Q2X
QOR
QOS
R89
R9I
RNI
RNS
ROL
RPM
RPX
RRX
RSV
RZK
S16
S1Z
S26
S27
S28
S3A
S3B
SAP
SBL
SCLPG
SDH
SDM
SHX
SISQX
SNE
SNPRN
SNX
SOHCF
SOJ
SPISZ
SRMVM
SSLCW
SSXJD
STPWE
SV3
SZN
T13
T16
TSG
TSK
TSV
TUC
TWZ
U2A
U9L
UG4
UKHRP
UOJIU
UTJUX
UZXMN
VC2
VFIZW
W23
W48
WH7
WJK
WK8
X7M
YLTOR
Z45
Z7U
Z7V
Z7W
Z7X
Z7Y
Z81
Z82
Z83
Z87
Z88
Z8O
Z8P
Z8Q
Z8R
Z8S
Z8V
Z8W
Z91
ZGI
ZMTXR
ZOVNA
~02
~KM
AASML
AAYXX
ABDBE
ABFSG
ACSTC
ADHKG
AEZWR
AFHIU
AGQPQ
AHPBZ
AHWEU
AIXLP
AYFIA
CITATION
GROUPED_DOAJ
PHGZM
PHGZT
PJZUB
PPXIY
PQGLB
PUEGO
CGR
CUY
CVF
ECM
EIF
NPM
7QL
7QP
7QR
7SS
7T5
7T7
7TK
7TM
7TO
7U7
7U9
7XB
8FD
8FK
C1K
FR3
H94
K9.
M7N
MBDVC
P64
PKEHL
PQEST
PQUKI
PRINS
Q9U
RC3
7X8
7S9
L.6
5PM
ADTOC
UNPAY
ID FETCH-LOGICAL-c573t-a697dfd7b12f751fc5889fa2196cd28cc6e2fc8c1457d1e9c83b301a68e0db323
IEDL.DBID UNPAY
ISSN 1420-682X
1420-9071
IngestDate Wed Aug 20 00:16:58 EDT 2025
Tue Sep 30 16:53:53 EDT 2025
Wed Oct 01 13:47:39 EDT 2025
Fri Sep 05 08:44:45 EDT 2025
Wed Aug 13 07:43:46 EDT 2025
Thu Apr 03 06:51:31 EDT 2025
Wed Oct 01 01:39:17 EDT 2025
Thu Apr 24 22:57:38 EDT 2025
Fri Feb 21 02:45:49 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 3
Keywords IFN-α
IFN-β
Tumor immunity
cGAS
Oncolytic virotherapy
STING
Radiation therapy
Language English
License 2022. The Author(s).
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
cc-by
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c573t-a697dfd7b12f751fc5889fa2196cd28cc6e2fc8c1457d1e9c83b301a68e0db323
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ORCID 0000-0003-2744-427X
OpenAccessLink https://proxy.k.utb.cz/login?url=https://link.springer.com/content/pdf/10.1007/s00018-022-04219-z.pdf
PMID 35292881
PQID 2639123140
PQPubID 54068
PageCount 1
ParticipantIDs unpaywall_primary_10_1007_s00018_022_04219_z
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8924142
proquest_miscellaneous_2648854437
proquest_miscellaneous_2640047447
proquest_journals_2639123140
pubmed_primary_35292881
crossref_citationtrail_10_1007_s00018_022_04219_z
crossref_primary_10_1007_s00018_022_04219_z
springer_journals_10_1007_s00018_022_04219_z
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2022-03-01
PublicationDateYYYYMMDD 2022-03-01
PublicationDate_xml – month: 03
  year: 2022
  text: 2022-03-01
  day: 01
PublicationDecade 2020
PublicationPlace Cham
PublicationPlace_xml – name: Cham
– name: Switzerland
– name: Basel
PublicationTitle Cellular and molecular life sciences : CMLS
PublicationTitleAbbrev Cell. Mol. Life Sci
PublicationTitleAlternate Cell Mol Life Sci
PublicationYear 2022
Publisher Springer International Publishing
Springer Nature B.V
Publisher_xml – name: Springer International Publishing
– name: Springer Nature B.V
References Luteijn, Zaver, Gowen (CR30) 2019; 573
Riley, Hansen, Brimnes (CR53) 2015; 94
Harding, Benci, Irianto (CR137) 2017; 548
Zhang, Sun, Rao (CR41) 2014; 74
Komdeur, Singh, van de Wall (CR104) 2021; 29
Puzanov, Milhem, Minor (CR153) 2016; 34
Weihrauch, Richly, von Bergwelt-Baildon (CR131) 2015; 51
Haymaker, Andtbacka, Johnson (CR123) 2020; 31
Cheng, Lemke-Miltner, Wongpattaraworakul (CR128) 2020; 8
Wu, Andzinski, Kasnitz (CR59) 2015; 137
Zoglmeier, Bauer, Noerenberg (CR68) 2011; 17
Yoon, Park, Shigemoto (CR43) 2016; 7
Bald, Landsberg, Lopez-Ramos (CR116) 2014; 4
Jang, Economides, Moniz (CR89) 2021; 4
Borden (CR11) 2019; 18
Swann, Hayakawa, Zerafa (CR49) 2007; 178
Shoushtari, Olszanski, Nyakas (CR161) 2021; 32
Arwert, Milford, Rullan (CR42) 2020; 22
Jiang, Zhang, Tian, Zhang (CR52) 2013; 20
Sharma, Carvajal, Hanna (CR122) 2021; 39
Sprooten, Agostinis, Garg (CR4) 2019; 348
Banerjee, Middya, Basu (CR90) 2018; 6
Meric-Bernstam, Sandhu, Hamid (CR140) 2019; 37
Wang, Donnelly, Jiang (CR84) 2021; 12
Wang, Guan, Lv (CR24) 2018; 48
Kim, Kim, Kim (CR79) 2019; 13
Wang, Hu, Chen (CR136) 2017; 114
Si, Liang, Bugno (CR166) 2021; 71
Ma, Li, Yu (CR38) 2015; 16
Parker, Rautela, Hertzog (CR3) 2016; 16
Kuryk, Moller, Jaderberg (CR160) 2019; 8
Panagioti, Kurokawa, Viker (CR164) 2021; 131
Sharabi, Tsokos, Ding (CR61) 2018; 17
Tozer, Kanthou, Baguley (CR83) 2005; 5
Mayadev, Nunes, Li (CR147) 2020; 30
Burnette, Liang, Lee (CR95) 2011; 71
Aznar, Planelles, Perez-Olivares (CR118) 2019; 7
Ferris, Gross, Nemunaitis (CR157) 2014; 32
Hervas-Stubbs, Perez-Gracia, Rouzaut (CR9) 2011; 17
Ribas, Medina, Kummar (CR126) 2018; 8
Anz, Rapp, Eiber (CR64) 2015; 75
Lhuillier, Vanpouille-Box, Galluzzi (CR143) 2018; 52
Gao, Ascano, Wu (CR21) 2013; 153
Brown, Mosaheb, Mohme (CR101) 2021; 12
Ribas, Dummer, Puzanov (CR154) 2017; 170
Jacquelot, Yamazaki, Roberti (CR114) 2019; 29
Lan, Moustafa, Knoll (CR151) 2021; 39
Pestka, Krause, Walter (CR5) 2004; 202
Zhao, Xue, Pan (CR31) 2019; 234
Demaria, De Gassart, Coso (CR37) 2015; 112
Silk, Kaufman, Gabrail (CR163) 2017; 77
Zhou, Zhang, Wang (CR46) 2020; 4
Patel, Tolcher, Rasco (CR121) 2021; 39
Jaillon, Ponzetta, Di Mitri (CR54) 2020; 20
Hashimoto, Ueda, Narumi (CR62) 2014; 21
Wang, Campos, Gallotta (CR125) 2016; 113
Ehnfors, Kost-Alimova, Persson (CR39) 2009; 16
Jablonska, Wu, Andzinski (CR56) 2014; 134
Reilley, Morrow, Ager (CR134) 2019; 7
Sharma, Hu-Lieskovan, Wargo, Ribas (CR112) 2017; 168
Brockwell, Owen, Zanker (CR117) 2017; 5
Feng, Tubbs, Zhang (CR96) 2020; 39
Curti, Richards, Hallmeyer (CR162) 2017; 77
Platanitis, Demiroz, Schneller (CR14) 2019; 10
Harrington, Brody, Ingham (CR141) 2018; 30
Aranda, Vacchelli, Obrist (CR75) 2014; 3
Andzinski, Kasnitz, Stahnke (CR57) 2016; 138
Ribas, Medina, Kirkwood (CR129) 2021
Vanpouille-Box, Alard, Aryankalayil (CR35) 2017; 8
Meric-Bernstam, Larkin, Tabernero, Bonini (CR113) 2021; 397
Saleiro, Platanias (CR15) 2019; 43
Kapp, Volz, Oswald (CR133) 2019; 8
Apetoh, Ghiringhelli, Tesniere (CR26) 2007; 13
Deng, Liang, Xu (CR34) 2014; 41
Corrales, Glickman, McWhirter (CR40) 2015; 11
Patel, Rasco, Johnson (CR120) 2020; 8
Sistigu, Yamazaki, Vacchelli (CR32) 2014; 20
Bourgeois-Daigneault, Roy, Aitken (CR105) 2018; 10
Li, Shi, Zhang (CR67) 2021; 6
Sagiv-Barfi, Czerwinski, Levy (CR77) 2018; 10
Andtbacka, Ross, Agarwala (CR158) 2017; 35
Salvagno, Ciampricotti, Tuit (CR94) 2019; 21
Ablasser, Schmid-Burgk, Hemmerling (CR36) 2013; 503
Chen, Cao, Markelc (CR47) 2019; 129
Vollmer, Krieg (CR81) 2009; 61
Wu, Sun, Chen (CR20) 2013; 339
Evgin, Huff, Wongthida (CR109) 2020; 11
Smith, Garcia-Martinez, Pitter (CR127) 2018; 7
Lv, Chen, Zhang (CR25) 2020; 30
Isaacs, Lindenmann (CR1) 1957; 147
Hui, Ozguroglu, Villegas (CR146) 2019; 20
Stark, Darnell (CR10) 2012; 36
Sivick, Desbien, Glickman (CR138) 2018; 25
Melero, Quetglas, Reboredo (CR103) 2015; 75
Vacchelli, Bloy, Aranda (CR145) 2016; 5
Sancho, Joffre, Keller (CR28) 2009; 458
Harrington, Kong, Mach (CR156) 2020; 26
Adamus, Kortylewski (CR74) 2018; 22
Saccheri, Pozzi, Avogadri (CR29) 2010; 2
Frank, Reagan, Bartlett (CR97) 2018; 8
Andzinski, Wu, Lienenklaus (CR55) 2015; 136
Tsuchiya, Zhang, Iwama (CR111) 2019; 29
Chen, Sun, Yang (CR70) 2021; 6
Brody, Ai, Czerwinski (CR82) 2010; 28
Fend, Yamazaki, Remy (CR110) 2017; 77
Swiecki, Colonna (CR16) 2015; 15
Zitvogel, Galluzzi, Kepp (CR72) 2015; 15
Perry, Tian, Sengottuvel (CR80) 2020; 14
Marcus, Mao, Lensink-Vasan (CR50) 2018; 49
Kang, Demaria, Formenti (CR144) 2016; 4
Fuertes, Kacha, Kline (CR19) 2011; 208
Bhagchandani, Johnson, Irvine (CR119) 2021; 175
Yang, Zhang, Fu (CR93) 2014; 25
Nuhn, De Koker, Van Lint (CR78) 2018; 30
Sisirak, Faget, Gobert (CR66) 2012; 72
Lee, Yang, Kim (CR139) 2021; 9
Leventhal, Sokolovska, Li (CR142) 2020; 11
Kwon, Drake, Scher (CR149) 2014; 15
Oritani, Kanakura (CR6) 2005; 9
Gresser, Bourali, Levy (CR45) 1969; 63
Roy, Geoffroy, Marguerie (CR106) 2021; 12
Jablonska, Leschner, Westphal (CR58) 2010; 120
Zamarin, Ricca, Sadekova (CR107) 2018; 128
Yokota, Isei, Uhara (CR159) 2019; 30
Lazear, Schoggins, Diamond (CR7) 2019; 50
Zamarin, Holmgaard, Subudhi (CR102) 2014; 6
Nunez, Andreani, Crespo (CR33) 2012; 72
Ramelyte, Tastanova, Balazs (CR99) 2021; 39
Muller, Aigner, Stoiber (CR51) 2017; 8
Desjardins, Gromeier, Herndon (CR100) 2018; 379
Butler, Robert, Negrier (CR124) 2019; 37
Levy, Kessler, Pine, Darnell (CR12) 1989; 3
Frega, Wu, Le Naour (CR76) 2020; 9
Butterfield, Vujanovic, Santos (CR48) 2019; 7
Corrales, McWhirter, Dubensky, Gajewski (CR23) 2016; 126
Bacher, Raker, Hofmann (CR63) 2013; 73
Senan, Okamoto, Lee (CR148) 2020; 21
Kessler, Veals, Fu, Levy (CR13) 1990; 4
Broad, Jones, Teske (CR44) 2021; 124
Mender, Zhang, Ren (CR165) 2020; 38
Woo, Fuertes, Corrales (CR18) 2014; 41
Lande, Gregorio, Facchinetti (CR27) 2007; 449
Yang, Adam, Clemens (CR91) 2018; 78
Andzinski, Spanier, Kasnitz (CR17) 2016; 139
Da Gama, Parakh, Andrews (CR115) 2018; 9
Field, Tytell, Lampson, Hilleman (CR69) 1967; 58
Davar, Karunamurthy, Hartman (CR130) 2020; 8
Drobits, Holcmann, Amberg (CR73) 2012; 122
Fu, Kanne, Leong (CR135) 2015; 7
Platanias (CR8) 2005; 5
Xu, Palmer, Robeson (CR85) 2021; 218
Isaacs, Lindenmann, Valentine (CR2) 1957; 147
Thomas, Ponce-Aix, Navarro (CR132) 2018; 29
Cheng, Watkins-Schulz, Junkins (CR88) 2018; 3
Poh (CR98) 2016; 6
Long, Dummer, Ribas (CR155) 2016; 34
Stagg, Loi, Divisekera (CR92) 2011; 108
Andtbacka, Kaufman, Collichio (CR152) 2015; 33
Hirata, Hashimoto, Shibasaki (CR65) 2019; 26
Huang, Li, Lemos (CR71) 2013; 191
Walsh, Bastin, Chen (CR108) 2019; 129
Lara, Douillard, Nakagawa (CR86) 2011; 29
Le Naour, Zitvogel, Galluzzi (CR87) 2020; 9
Chan, Choi, Jackson, Lim (CR150) 2021; 151
Pylaeva, Lang, Jablonska (CR60) 2016; 7
Zhang, Bai, Chen (CR22) 2020; 53
L Corrales (4219_CR23) 2016; 126
D Zamarin (4219_CR107) 2018; 128
P Gao (4219_CR21) 2013; 153
A Hirata (4219_CR65) 2019; 26
W Jiang (4219_CR52) 2013; 20
E Pylaeva (4219_CR60) 2016; 7
N Yoon (4219_CR43) 2016; 7
J Wu (4219_CR20) 2013; 339
SC Jang (4219_CR89) 2021; 4
DJ Da Gama (4219_CR115) 2018; 9
L Nuhn (4219_CR78) 2018; 30
J Fu (4219_CR135) 2015; 7
H Hashimoto (4219_CR62) 2014; 21
JL Perry (4219_CR80) 2020; 14
L Zhou (4219_CR46) 2020; 4
X Zhang (4219_CR22) 2020; 53
V Sisirak (4219_CR66) 2012; 72
A Ribas (4219_CR129) 2021
J Chen (4219_CR47) 2019; 129
T Adamus (4219_CR74) 2018; 22
K Wang (4219_CR84) 2021; 12
DG Roy (4219_CR106) 2021; 12
SY Kim (4219_CR79) 2019; 13
RH Andtbacka (4219_CR152) 2015; 33
F Ma (4219_CR38) 2015; 16
F Meric-Bernstam (4219_CR113) 2021; 397
L Deng (4219_CR34) 2014; 41
MJ Frank (4219_CR97) 2018; 8
D Zamarin (4219_CR102) 2014; 6
I Sagiv-Barfi (4219_CR77) 2018; 10
A Ablasser (4219_CR36) 2013; 503
Y Lan (4219_CR151) 2021; 39
CH Riley (4219_CR53) 2015; 94
J Chen (4219_CR70) 2021; 6
JB Swann (4219_CR49) 2007; 178
D Davar (4219_CR130) 2020; 8
A Ribas (4219_CR154) 2017; 170
MJ Reilley (4219_CR134) 2019; 7
G Frega (4219_CR76) 2020; 9
M Lv (4219_CR25) 2020; 30
KJ Harrington (4219_CR141) 2018; 30
AW Silk (4219_CR163) 2017; 77
DE Levy (4219_CR12) 1989; 3
S Senan (4219_CR148) 2020; 21
BC Burnette (4219_CR95) 2011; 71
D Sancho (4219_CR28) 2009; 458
J Zhao (4219_CR31) 2019; 234
NG Nunez (4219_CR33) 2012; 72
C Lhuillier (4219_CR143) 2018; 52
ED Kwon (4219_CR149) 2014; 15
I Gresser (4219_CR45) 1969; 63
J Stagg (4219_CR92) 2011; 108
I Mender (4219_CR165) 2020; 38
M Swiecki (4219_CR16) 2015; 15
M Smith (4219_CR127) 2018; 7
N Xu (4219_CR85) 2021; 218
W Si (4219_CR166) 2021; 71
C Salvagno (4219_CR94) 2019; 21
N Cheng (4219_CR88) 2018; 3
C Haymaker (4219_CR123) 2020; 31
MC Brown (4219_CR101) 2021; 12
N Tsuchiya (4219_CR111) 2019; 29
M Patel (4219_CR120) 2020; 8
SR Walsh (4219_CR108) 2019; 129
GV Long (4219_CR155) 2016; 34
F Saccheri (4219_CR29) 2010; 2
RHI Andtbacka (4219_CR158) 2017; 35
DS Kessler (4219_CR13) 1990; 4
GM Tozer (4219_CR83) 2005; 5
J Kang (4219_CR144) 2016; 4
L Andzinski (4219_CR55) 2015; 136
BS Parker (4219_CR3) 2016; 16
J Jablonska (4219_CR58) 2010; 120
S Wang (4219_CR125) 2016; 113
B Curti (4219_CR162) 2017; 77
LC Platanias (4219_CR8) 2005; 5
EC Borden (4219_CR11) 2019; 18
KJ Harrington (4219_CR156) 2020; 26
A Sharabi (4219_CR61) 2018; 17
JD Brody (4219_CR82) 2010; 28
MC Bourgeois-Daigneault (4219_CR105) 2018; 10
KE Sivick (4219_CR138) 2018; 25
J Mayadev (4219_CR147) 2020; 30
NK Brockwell (4219_CR117) 2017; 5
D Saleiro (4219_CR15) 2019; 43
A Poh (4219_CR98) 2016; 6
A Sistigu (4219_CR32) 2014; 20
O Demaria (4219_CR37) 2015; 112
CF Wu (4219_CR59) 2015; 137
N Bacher (4219_CR63) 2013; 73
SM Harding (4219_CR137) 2017; 548
PN Lara Jr (4219_CR86) 2011; 29
M Thomas (4219_CR132) 2018; 29
K Li (4219_CR67) 2021; 6
AK Field (4219_CR69) 1967; 58
L Kuryk (4219_CR160) 2019; 8
E Panagioti (4219_CR164) 2021; 131
FL Komdeur (4219_CR104) 2021; 29
E Platanitis (4219_CR14) 2019; 10
L Corrales (4219_CR40) 2015; 11
MB Fuertes (4219_CR19) 2011; 208
A Desjardins (4219_CR100) 2018; 379
LH Butterfield (4219_CR48) 2019; 7
HY Chan (4219_CR150) 2021; 151
L Apetoh (4219_CR26) 2007; 13
L Zitvogel (4219_CR72) 2015; 15
MA Aznar (4219_CR118) 2019; 7
DS Leventhal (4219_CR142) 2020; 11
J Yang (4219_CR91) 2018; 78
S Jaillon (4219_CR54) 2020; 20
F Meric-Bernstam (4219_CR140) 2019; 37
M Sharma (4219_CR122) 2021; 39
T Bald (4219_CR116) 2014; 4
N Jacquelot (4219_CR114) 2019; 29
F Aranda (4219_CR75) 2014; 3
S Pestka (4219_CR5) 2004; 202
L Huang (4219_CR71) 2013; 191
A Isaacs (4219_CR1) 1957; 147
J Vollmer (4219_CR81) 2009; 61
D Anz (4219_CR64) 2015; 75
J Jablonska (4219_CR56) 2014; 134
L Fend (4219_CR110) 2017; 77
J Sprooten (4219_CR4) 2019; 348
C Vanpouille-Box (4219_CR35) 2017; 8
K Oritani (4219_CR6) 2005; 9
B Drobits (4219_CR73) 2012; 122
A Isaacs (4219_CR2) 1957; 147
RV Broad (4219_CR44) 2021; 124
X Yang (4219_CR93) 2014; 25
S Hervas-Stubbs (4219_CR9) 2011; 17
AN Shoushtari (4219_CR161) 2021; 32
C Wang (4219_CR24) 2018; 48
A Ribas (4219_CR126) 2018; 8
K Kapp (4219_CR133) 2019; 8
A Marcus (4219_CR50) 2018; 49
E Ramelyte (4219_CR99) 2021; 39
EN Arwert (4219_CR42) 2020; 22
X Feng (4219_CR96) 2020; 39
E Vacchelli (4219_CR145) 2016; 5
H Wang (4219_CR136) 2017; 114
HM Lazear (4219_CR7) 2019; 50
M Banerjee (4219_CR90) 2018; 6
I Puzanov (4219_CR153) 2016; 34
L Andzinski (4219_CR17) 2016; 139
L Evgin (4219_CR109) 2020; 11
J Ehnfors (4219_CR39) 2009; 16
RL Ferris (4219_CR157) 2014; 32
L Muller (4219_CR51) 2017; 8
C Zoglmeier (4219_CR68) 2011; 17
K Yokota (4219_CR159) 2019; 30
SR Woo (4219_CR18) 2014; 41
Y Zhang (4219_CR41) 2014; 74
GR Stark (4219_CR10) 2012; 36
P Sharma (4219_CR112) 2017; 168
I Melero (4219_CR103) 2015; 75
R Lande (4219_CR27) 2007; 449
MR Weihrauch (4219_CR131) 2015; 51
SJ Lee (4219_CR139) 2021; 9
R Hui (4219_CR146) 2019; 20
RD Luteijn (4219_CR30) 2019; 573
J Le Naour (4219_CR87) 2020; 9
S Bhagchandani (4219_CR119) 2021; 175
L Andzinski (4219_CR57) 2016; 138
MO Butler (4219_CR124) 2019; 37
MR Patel (4219_CR121) 2021; 39
Y Cheng (4219_CR128) 2020; 8
References_xml – volume: 15
  start-page: 471
  year: 2015
  end-page: 485
  ident: CR16
  article-title: The multifaceted biology of plasmacytoid dendritic cells
  publication-title: Nat Rev Immunol
– volume: 136
  start-page: 572
  year: 2015
  end-page: 583
  ident: CR55
  article-title: Delayed apoptosis of tumor associated neutrophils in the absence of endogenous IFN-beta
  publication-title: Int J Cancer
– volume: 5
  start-page: 375
  year: 2005
  end-page: 386
  ident: CR8
  article-title: Mechanisms of type-I- and type-II-interferon-mediated signalling
  publication-title: Nat Rev Immunol
– volume: 8
  start-page: A185
  year: 2020
  end-page: A186
  ident: CR130
  article-title: 303 Phase II trial of neoadjuvant nivolumab (Nivo) and intra-tumoral (IT) CMP-001 in high-risk resectable melanoma (Neo-C-Nivo): final results
  publication-title: J Immunother Cancer
– volume: 4
  start-page: e1900237
  year: 2020
  ident: CR46
  article-title: A dual role of type I interferons in antitumor immunity
  publication-title: Adv Biosyst
– volume: 8
  start-page: 304
  year: 2017
  ident: CR51
  article-title: Type I Interferons and natural killer cell regulation in cancer
  publication-title: Front Immunol
– volume: 32
  start-page: 6082
  year: 2014
  end-page: 6082
  ident: CR157
  article-title: Phase I trial of intratumoral therapy using HF10, an oncolytic HSV-1, demonstrates safety in HSV+/HSV- patients with refractory and superficial cancers
  publication-title: J Clin Oncol
– volume: 112
  start-page: 15408
  year: 2015
  end-page: 15413
  ident: CR37
  article-title: STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity
  publication-title: Proc Natl Acad Sci U S A
– volume: 12
  start-page: 2626
  year: 2021
  ident: CR106
  article-title: Adjuvant oncolytic virotherapy for personalized anti-cancer vaccination
  publication-title: Nat Commun
– volume: 36
  start-page: 503
  year: 2012
  end-page: 514
  ident: CR10
  article-title: The JAK-STAT pathway at twenty
  publication-title: Immunity
– volume: 52
  start-page: 125
  year: 2018
  end-page: 134
  ident: CR143
  article-title: Emerging biomarkers for the combination of radiotherapy and immune checkpoint blockers
  publication-title: Semin Cancer Biol
– volume: 6
  start-page: 4
  year: 2021
  ident: CR70
  article-title: Reprogramming immunosuppressive myeloid cells by activated T cells promotes the response to anti-PD-1 therapy in colorectal cancer
  publication-title: Signal Transduct Target Ther
– volume: 7
  start-page: 283ra252
  year: 2015
  end-page: 283ra252
  ident: CR135
  article-title: STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade
  publication-title: Sci Transl Med
– volume: 7
  start-page: 113
  year: 2019
  ident: CR48
  article-title: Multiple antigen-engineered DC vaccines with or without IFNalpha to promote antitumor immunity in melanoma
  publication-title: J Immunother Cancer
– volume: 9
  start-page: 1777624
  year: 2020
  ident: CR87
  article-title: Trial watch: STING agonists in cancer therapy
  publication-title: Oncoimmunology
– volume: 94
  start-page: 227
  year: 2015
  end-page: 234
  ident: CR53
  article-title: Expansion of circulating CD56bright natural killer cells in patients with JAK2-positive chronic myeloproliferative neoplasms during treatment with interferon-alpha
  publication-title: Eur J Haematol
– volume: 39
  start-page: e104036
  year: 2020
  ident: CR96
  article-title: ATR inhibition potentiates ionizing radiation-induced interferon response via cytosolic nucleic acid-sensing pathways
  publication-title: EMBO J
– volume: 34
  start-page: 9568
  year: 2016
  end-page: 9568
  ident: CR155
  article-title: Efficacy analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma
  publication-title: J Clin Oncol
– volume: 39
  start-page: 2512
  year: 2021
  end-page: 2512
  ident: CR121
  article-title: BDB001, an intravenously administered toll-like receptor 7 and 8 (TLR7/8) agonist, in combination with pembrolizumab in advanced solid tumors: phase 1 safety and efficacy results
  publication-title: J Clin Oncol
– volume: 120
  start-page: 1151
  year: 2010
  end-page: 1164
  ident: CR58
  article-title: Neutrophils responsive to endogenous IFN-beta regulate tumor angiogenesis and growth in a mouse tumor model
  publication-title: J Clin Invest
– volume: 131
  start-page: e141614
  year: 2021
  ident: CR164
  article-title: Immunostimulatory bacterial antigen-armed oncolytic measles virotherapy significantly increases the potency of anti-PD1 checkpoint therapy
  publication-title: J Clin Invest
– volume: 208
  start-page: 2005
  year: 2011
  end-page: 2016
  ident: CR19
  article-title: Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells
  publication-title: J Exp Med
– volume: 153
  start-page: 1094
  year: 2013
  end-page: 1107
  ident: CR21
  article-title: Cyclic [G(2',5')pA(3',5')p] is the metazoan second messenger produced by DNA-activated cyclic GMP-AMP synthase
  publication-title: Cell
– volume: 7
  start-page: 116
  year: 2019
  ident: CR118
  article-title: Immunotherapeutic effects of intratumoral nanoplexed poly I:C
  publication-title: J Immunother Cancer
– volume: 30
  start-page: e1803397
  year: 2018
  ident: CR78
  article-title: Nanoparticle-conjugate TLR7/8 agonist localized immunotherapy provokes safe antitumoral responses
  publication-title: Adv Mater
– volume: 11
  start-page: 2739
  year: 2020
  ident: CR142
  article-title: Immunotherapy with engineered bacteria by targeting the STING pathway for anti-tumor immunity
  publication-title: Nat Commun
– volume: 31
  start-page: S736
  year: 2020
  ident: CR123
  article-title: 1083MO Final results from ILLUMINATE-204, a phase I/II trial of intratumoral tilsotolimod in combination with ipilimumab in PD-1 inhibitor refractory advanced melanoma
  publication-title: Ann Oncol
– volume: 138
  start-page: 1982
  year: 2016
  end-page: 1993
  ident: CR57
  article-title: Type I IFNs induce anti-tumor polarization of tumor associated neutrophils in mice and human
  publication-title: Int J Cancer
– volume: 73
  start-page: 5647
  year: 2013
  end-page: 5656
  ident: CR63
  article-title: Interferon-alpha suppresses cAMP to disarm human regulatory T cells
  publication-title: Cancer Res
– volume: 108
  start-page: 7142
  year: 2011
  end-page: 7147
  ident: CR92
  article-title: Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy
  publication-title: Proc Natl Acad Sci U S A
– volume: 63
  start-page: 51
  year: 1969
  end-page: 57
  ident: CR45
  article-title: Increased survival in mice inoculated with tumor cells and treated with interferon preparations
  publication-title: Proc Natl Acad Sci U S A
– volume: 16
  start-page: 749
  year: 2009
  end-page: 757
  ident: CR39
  article-title: Horizontal transfer of tumor DNA to endothelial cells in vivo
  publication-title: Cell Death Differ
– volume: 6
  start-page: 362
  year: 2021
  ident: CR67
  article-title: Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer
  publication-title: Signal Transduct Target Ther
– volume: 348
  start-page: 217
  year: 2019
  end-page: 262
  ident: CR4
  article-title: Type I interferons and dendritic cells in cancer immunotherapy
  publication-title: Int Rev Cell Mol Biol
– volume: 74
  start-page: 2986
  year: 2014
  end-page: 2998
  ident: CR41
  article-title: Fatty acid-binding protein E-FABP restricts tumor growth by promoting IFN-beta responses in tumor-associated macrophages
  publication-title: Cancer Res
– volume: 29
  start-page: 2076
  year: 2018
  end-page: 2084
  ident: CR132
  article-title: Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: results from the exploratory, controlled, randomized, international phase II IMPULSE study
  publication-title: Ann Oncol
– volume: 8
  start-page: A199
  year: 2020
  ident: CR120
  article-title: 324 BDB001, a Toll-Like receptor 7 and 8 (TLR7/8) agonist, can be safely administered intravenously and shows clinical responses in advanced solid tumors
  publication-title: J Immunother Cancer
– volume: 13
  start-page: 12671
  year: 2019
  end-page: 12686
  ident: CR79
  article-title: Lyophilizable and multifaceted toll-like receptor 7/8 agonist-loaded nanoemulsion for the reprogramming of tumor microenvironments and enhanced cancer immunotherapy
  publication-title: ACS Nano
– volume: 25
  start-page: 3074
  year: 2018
  end-page: 3085
  ident: CR138
  article-title: Magnitude of therapeutic STING activation determines CD8(+) T cell-mediated anti-tumor immunity
  publication-title: Cell Rep
– volume: 11
  start-page: 1018
  year: 2015
  end-page: 1030
  ident: CR40
  article-title: Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity
  publication-title: Cell Rep
– volume: 134
  start-page: 1346
  year: 2014
  end-page: 1358
  ident: CR56
  article-title: CXCR2-mediated tumor-associated neutrophil recruitment is regulated by IFN-beta
  publication-title: Int J Cancer
– volume: 39
  start-page: 2549
  year: 2021
  end-page: 2549
  ident: CR122
  article-title: Preliminary results from a phase 1/2 study of BDC-1001, a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), in patients (pts) with advanced HER2-expressing solid tumors
  publication-title: J Clin Oncol
– volume: 72
  start-page: 592
  year: 2012
  end-page: 603
  ident: CR33
  article-title: IFNbeta produced by TLR4-activated tumor cells is involved in improving the antitumoral immune response
  publication-title: Cancer Res
– volume: 16
  start-page: 202
  year: 2015
  end-page: 212
  ident: CR38
  article-title: Positive feedback regulation of type I interferon by the interferon-stimulated gene STING
  publication-title: EMBO Rep
– volume: 26
  start-page: 334
  year: 2019
  end-page: 343
  ident: CR65
  article-title: Intratumoral IFN-alpha gene delivery reduces tumor-infiltrating regulatory T cells through the downregulation of tumor CCL17 expression
  publication-title: Cancer Gene Ther
– volume: 7
  start-page: e1526250
  year: 2018
  ident: CR127
  article-title: Trial Watch: Toll-like receptor agonists in cancer immunotherapy
  publication-title: Oncoimmunology
– volume: 38
  start-page: 400
  year: 2020
  end-page: 411
  ident: CR165
  article-title: Telomere Stress Potentiates STING-Dependent Anti-tumor Immunity
  publication-title: Cancer Cell
– volume: 168
  start-page: 707
  year: 2017
  end-page: 723
  ident: CR112
  article-title: Primary, adaptive, and acquired resistance to cancer immunotherapy
  publication-title: Cell
– volume: 7
  start-page: 323
  year: 2019
  ident: CR134
  article-title: TLR9 activation cooperates with T cell checkpoint blockade to regress poorly immunogenic melanoma
  publication-title: J Immunother Cancer
– volume: 20
  start-page: 1301
  year: 2014
  end-page: 1309
  ident: CR32
  article-title: Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy
  publication-title: Nat Med
– volume: 10
  start-page: 4eaan488
  year: 2018
  ident: CR77
  article-title: Eradication of spontaneous malignancy by local immunotherapy
  publication-title: Sci Transl Med
– volume: 218
  start-page: e20200844
  year: 2021
  ident: CR85
  article-title: STING agonist promotes CAR T cell trafficking and persistence in breast cancer
  publication-title: J Exp Med
– volume: 39
  start-page: 1388
  year: 2021
  end-page: 1403
  ident: CR151
  article-title: Simultaneous targeting of TGF-beta/PD-L1 synergizes with radiotherapy by reprogramming the tumor microenvironment to overcome immune evasion
  publication-title: Cancer Cell
– volume: 129
  start-page: 518
  year: 2019
  end-page: 530
  ident: CR108
  article-title: Type I IFN blockade uncouples immunotherapy-induced antitumor immunity and autoimmune toxicity
  publication-title: J Clin Invest
– volume: 17
  start-page: 2619
  year: 2011
  end-page: 2627
  ident: CR9
  article-title: Direct effects of type I interferons on cells of the immune system
  publication-title: Clin Cancer Res
– volume: 129
  start-page: 4224
  year: 2019
  end-page: 4238
  ident: CR47
  article-title: Type I IFN protects cancer cells from CD8+ T cell–mediated cytotoxicity after radiation
  publication-title: J Clin Investig
– volume: 151
  start-page: 375
  year: 2021
  end-page: 391
  ident: CR150
  article-title: Combination immunotherapy strategies for glioblastoma
  publication-title: J Neurooncol
– volume: 178
  start-page: 7540
  year: 2007
  end-page: 7549
  ident: CR49
  article-title: Type I IFN contributes to NK cell homeostasis, activation, and antitumor function
  publication-title: J Immunol
– volume: 21
  start-page: 511
  year: 2019
  end-page: 521
  ident: CR94
  article-title: Therapeutic targeting of macrophages enhances chemotherapy efficacy by unleashing type I interferon response
  publication-title: Nat Cell Biol
– volume: 548
  start-page: 466
  year: 2017
  end-page: 470
  ident: CR137
  article-title: Mitotic progression following DNA damage enables pattern recognition within micronuclei
  publication-title: Nature
– volume: 20
  start-page: 1062
  year: 2013
  end-page: 1069
  ident: CR52
  article-title: hIFN-alpha gene modification augments human natural killer cell line anti-human hepatocellular carcinoma function
  publication-title: Gene Ther
– volume: 10
  start-page: 2921
  year: 2019
  ident: CR14
  article-title: A molecular switch from STAT2-IRF9 to ISGF3 underlies interferon-induced gene transcription
  publication-title: Nat Commun
– volume: 458
  start-page: 899
  year: 2009
  end-page: 903
  ident: CR28
  article-title: Identification of a dendritic cell receptor that couples sensing of necrosis to immunity
  publication-title: Nature
– volume: 8
  start-page: 1258
  year: 2018
  end-page: 1269
  ident: CR97
  article-title: In situ vaccination with a TLR9 agonist and local low-dose radiation induces systemic responses in untreated indolent lymphoma
  publication-title: Cancer Discov
– volume: 16
  start-page: 131
  year: 2016
  end-page: 144
  ident: CR3
  article-title: Antitumour actions of interferons: implications for cancer therapy
  publication-title: Nat Rev Cancer
– volume: 20
  start-page: 485
  year: 2020
  end-page: 503
  ident: CR54
  article-title: Neutrophil diversity and plasticity in tumour progression and therapy
  publication-title: Nat Rev Cancer
– volume: 147
  start-page: 268
  year: 1957
  end-page: 273
  ident: CR2
  article-title: Virus interference. II. Some properties of interferon
  publication-title: Proc R Soc Lond B Biol Sci
– volume: 37
  start-page: TPS9599
  year: 2019
  end-page: TPS9599
  ident: CR124
  article-title: ILLUMINATE 301: A randomized phase 3 study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients with advanced melanoma following progression on or after anti-PD-1 therapy
  publication-title: J Clin Oncol
– volume: 21
  start-page: e84
  year: 2020
  end-page: e88
  ident: CR148
  article-title: Design and rationale for a phase III, randomized, placebo-controlled trial of durvalumab with or without tremelimumab after concurrent chemoradiotherapy for patients With limited-stage small-cell lung cancer: the ADRIATIC study
  publication-title: Clin Lung Cancer
– volume: 4
  start-page: 674
  year: 2014
  end-page: 687
  ident: CR116
  article-title: Immune cell-poor melanomas benefit from PD-1 blockade after targeted type I IFN activation
  publication-title: Cancer Discov
– volume: 175
  start-page: 113803
  year: 2021
  ident: CR119
  article-title: Evolution of Toll-like receptor 7/8 agonist therapeutics and their delivery approaches: from antiviral formulations to vaccine adjuvants
  publication-title: Adv Drug Deliv Rev
– volume: 4
  start-page: 1753
  year: 1990
  end-page: 1765
  ident: CR13
  article-title: Interferon-alpha regulates nuclear translocation and DNA-binding affinity of ISGF3, a multimeric transcriptional activator
  publication-title: Genes Dev
– volume: 37
  start-page: 2507
  year: 2019
  end-page: 2507
  ident: CR140
  article-title: Phase Ib study of MIW815 (ADU-S100) in combination with spartalizumab (PDR001) in patients (pts) with advanced/metastatic solid tumors or lymphomas
  publication-title: J Clin Oncol
– volume: 202
  start-page: 8
  year: 2004
  end-page: 32
  ident: CR5
  article-title: Interferons, interferon-like cytokines, and their receptors
  publication-title: Immunol Rev
– volume: 43
  start-page: 101299
  year: 2019
  ident: CR15
  article-title: Interferon signaling in cancer Non-canonical pathways and control of intracellular immune checkpoints
  publication-title: Semin Immunol
– volume: 58
  start-page: 1004
  year: 1967
  end-page: 1010
  ident: CR69
  article-title: Inducers of interferon and host resistance. II. Multistranded synthetic polynucleotide complexes
  publication-title: Proc Natl Acad Sci U S A
– volume: 128
  start-page: 1413
  year: 2018
  end-page: 1428
  ident: CR107
  article-title: PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy
  publication-title: J Clin Invest
– volume: 2
  start-page: 44ra57
  year: 2010
  ident: CR29
  article-title: Bacteria-induced gap junctions in tumors favor antigen cross-presentation and antitumor immunity
  publication-title: Sci Transl Med
– volume: 17
  start-page: 1765
  year: 2011
  end-page: 1775
  ident: CR68
  article-title: CpG blocks immunosuppression by myeloid-derived suppressor cells in tumor-bearing mice
  publication-title: Clin Cancer Res
– volume: 5
  start-page: 871
  year: 2017
  end-page: 884
  ident: CR117
  article-title: Neoadjuvant interferons: critical for effective PD-1-based immunotherapy in TNBC
  publication-title: Cancer Immunol Res
– volume: 5
  start-page: 423
  year: 2005
  end-page: 435
  ident: CR83
  article-title: Disrupting tumour blood vessels
  publication-title: Nat Rev Cancer
– volume: 137
  start-page: 837
  year: 2015
  end-page: 847
  ident: CR59
  article-title: The lack of type I interferon induces neutrophil-mediated pre-metastatic niche formation in the mouse lung
  publication-title: Int J Cancer
– volume: 41
  start-page: 843
  year: 2014
  end-page: 852
  ident: CR34
  article-title: STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors
  publication-title: Immunity
– volume: 17
  start-page: 823
  year: 2018
  end-page: 844
  ident: CR61
  article-title: Regulatory T cells in the treatment of disease
  publication-title: Nat Rev Drug Discov
– volume: 71
  start-page: 2488
  year: 2011
  end-page: 2496
  ident: CR95
  article-title: The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity
  publication-title: Cancer Res
– volume: 339
  start-page: 826
  year: 2013
  end-page: 830
  ident: CR20
  article-title: Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA
  publication-title: Science
– volume: 20
  start-page: 1670
  year: 2019
  end-page: 1680
  ident: CR146
  article-title: Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study
  publication-title: Lancet Oncol
– volume: 8
  start-page: 15618
  year: 2017
  ident: CR35
  article-title: DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity
  publication-title: Nat Commun
– volume: 72
  start-page: 5188
  year: 2012
  end-page: 5197
  ident: CR66
  article-title: Impaired IFN-alpha production by plasmacytoid dendritic cells favors regulatory T-cell expansion that may contribute to breast cancer progression
  publication-title: Cancer Res
– volume: 25
  start-page: 37
  year: 2014
  end-page: 48
  ident: CR93
  article-title: Targeting the tumor microenvironment with interferon-beta bridges innate and adaptive immune responses
  publication-title: Cancer Cell
– volume: 7
  start-page: 629
  year: 2016
  ident: CR60
  article-title: The essential role of type I interferons in differentiation and activation of tumor-associated neutrophils
  publication-title: Front Immunol
– volume: 41
  start-page: 830
  year: 2014
  end-page: 842
  ident: CR18
  article-title: STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors
  publication-title: Immunity
– volume: 573
  start-page: 434
  year: 2019
  end-page: 438
  ident: CR30
  article-title: SLC19A1 transports immunoreactive cyclic dinucleotides
  publication-title: Nature
– volume: 114
  start-page: 1637
  year: 2017
  end-page: 1642
  ident: CR136
  article-title: cGAS is essential for the antitumor effect of immune checkpoint blockade
  publication-title: Proc Natl Acad Sci U S A
– volume: 61
  start-page: 195
  year: 2009
  end-page: 204
  ident: CR81
  article-title: Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists
  publication-title: Adv Drug Deliv Rev
– volume: 77
  start-page: 4146
  year: 2017
  end-page: 4157
  ident: CR110
  article-title: Immune checkpoint blockade, immunogenic chemotherapy or IFN-alpha blockade boost the local and abscopal effects of oncolytic virotherapy
  publication-title: Cancer Res
– volume: 13
  start-page: 1050
  year: 2007
  end-page: 1059
  ident: CR26
  article-title: Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy
  publication-title: Nat Med
– volume: 234
  start-page: 7051
  year: 2019
  end-page: 7061
  ident: CR31
  article-title: Toll-like receptor 3 agonist poly I: C reinforces the potency of cytotoxic chemotherapy via the TLR3-UNC93B1-IFN-beta signaling axis in paclitaxel-resistant colon cancer
  publication-title: J Cell Physiol
– volume: 113
  start-page: E7240
  year: 2016
  end-page: E7249
  ident: CR125
  article-title: Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8+ T cells
  publication-title: Proc Natl Acad Sci U S A
– volume: 77
  start-page: CT114
  year: 2017
  ident: CR162
  article-title: Abstract CT114: The MITCI (Phase 1b) study: A novelimmunotherapy combination of intralesional Coxsackievirus A21 and systemic ipilimumab in advanced melanoma patients with or without previous immune checkpoint therapy treatment
  publication-title: Cancer Res
– volume: 15
  start-page: 405
  year: 2015
  end-page: 414
  ident: CR72
  article-title: Type I interferons in anticancer immunity
  publication-title: Nat Rev Immunol
– volume: 3
  start-page: e120638
  year: 2018
  ident: CR88
  article-title: A nanoparticle-incorporated STING activator enhances antitumor immunity in PD-L1-insensitive models of triple-negative breast cancer
  publication-title: JCI Insight
– volume: 397
  start-page: 1010
  year: 2021
  end-page: 1022
  ident: CR113
  article-title: Enhancing anti-tumour efficacy with immunotherapy combinations
  publication-title: The Lancet
– volume: 12
  start-page: 4558
  year: 2021
  ident: CR84
  article-title: STING suppresses bone cancer pain via immune and neuronal modulation
  publication-title: Nat Commun
– volume: 10
  start-page: eaao1641
  year: 2018
  ident: CR105
  article-title: Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy
  publication-title: Sci Transl Med
– volume: 50
  start-page: 907
  year: 2019
  end-page: 923
  ident: CR7
  article-title: Shared and distinct functions of type I and type III interferons
  publication-title: Immunity
– volume: 449
  start-page: 564
  year: 2007
  end-page: 569
  ident: CR27
  article-title: Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide
  publication-title: Nature
– volume: 170
  start-page: 1109
  year: 2017
  end-page: 1119
  ident: CR154
  article-title: Oncolytic virotherapy promotes intratumoral T cell Infiltration and improves Anti-PD-1 immunotherapy
  publication-title: Cell
– volume: 35
  start-page: 9510
  year: 2017
  end-page: 9510
  ident: CR158
  article-title: Final results of a phase II multicenter trial of HF10, a replication-competent HSV-1 oncolytic virus, and ipilimumab combination treatment in patients with stage IIIB-IV unresectable or metastatic melanoma
  publication-title: J Clin Oncol
– volume: 147
  start-page: 258
  year: 1957
  end-page: 267
  ident: CR1
  article-title: Virus interference. I. the interferon
  publication-title: Proc R Soc Lond B Biol Sci
– volume: 139
  start-page: 1350
  year: 2016
  end-page: 1357
  ident: CR17
  article-title: Growing tumors induce a local STING dependent Type I IFN response in dendritic cells
  publication-title: Int J Cancer
– volume: 26
  start-page: 5153
  year: 2020
  end-page: 5161
  ident: CR156
  article-title: Talimogene laherparepvec and pembrolizumab in recurrent or metastatic squamous cell carcinoma of the head and neck (MASTERKEY-232): a multicenter, phase 1b study
  publication-title: Clin Cancer Res
– volume: 78
  start-page: 5554
  year: 2018
  ident: CR91
  article-title: Abstract 5554: Preclinical characterization of GSK532, a novel STING agonist with potent anti-tumor activity
  publication-title: Cancer Res
– volume: 8
  start-page: e1659096
  year: 2019
  ident: CR133
  article-title: Beneficial modulation of the tumor microenvironment and generation of anti-tumor responses by TLR9 agonist lefitolimod alone and in combination with checkpoint inhibitors
  publication-title: Oncoimmunology
– volume: 32
  start-page: S867
  year: 2021
  end-page: S905
  ident: CR161
  article-title: A pilot study of engineered adenovirus ONCOS-102 in combination with pembrolizumab (pembro) in checkpoint inhibitor refractory advanced or unresectable melanoma
  publication-title: Ann Oncol
– volume: 71
  start-page: 521
  year: 2021
  end-page: 533
  ident: CR166
  article-title: Lactobacillus rhamnosus GG induces cGAS/STING- dependent type I interferon and improves response to immune checkpoint blockade
  publication-title: Gut
– volume: 39
  start-page: 394
  year: 2021
  end-page: 406
  ident: CR99
  article-title: Oncolytic virotherapy-mediated anti-tumor response: a single-cell perspective
  publication-title: Cancer Cell
– volume: 29
  start-page: 162
  year: 2019
  end-page: 175
  ident: CR111
  article-title: Type I interferon delivery by iPSC-derived myeloid cells elicits antitumor Immunity via XCR1(+) dendritic cells
  publication-title: Cell Rep
– volume: 29
  start-page: 2965
  year: 2011
  end-page: 2971
  ident: CR86
  article-title: Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer
  publication-title: J Clin Oncol
– volume: 15
  start-page: 700
  year: 2014
  end-page: 712
  ident: CR149
  article-title: Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
  publication-title: Lancet Oncol
– volume: 22
  start-page: 56
  year: 2018
  end-page: 60
  ident: CR74
  article-title: The revival of CpG oligonucleotide-based cancer immunotherapies
  publication-title: Contemp Oncol (Pozn)
– volume: 3
  start-page: e29179
  year: 2014
  ident: CR75
  article-title: Trial watch: toll-like receptor agonists in oncological indications
  publication-title: Oncoimmunology
– volume: 51
  start-page: 146
  year: 2015
  end-page: 156
  ident: CR131
  article-title: Phase I clinical study of the toll-like receptor 9 agonist MGN1703 in patients with metastatic solid tumours
  publication-title: Eur J Cancer
– volume: 11
  start-page: 3187
  year: 2020
  ident: CR109
  article-title: Oncolytic virus-derived type I interferon restricts CAR T cell therapy
  publication-title: Nat Commun
– volume: 122
  start-page: 575
  year: 2012
  end-page: 585
  ident: CR73
  article-title: Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells
  publication-title: J Clin Invest
– volume: 9
  start-page: 411
  year: 2018
  ident: CR115
  article-title: Autoantibodies may predict immune-related toxicity: results from a phase I study of intralesional bacillus calmette-guerin followed by ipilimumab in patients with advanced metastatic melanoma
  publication-title: Front Immunol
– volume: 30
  start-page: 966
  year: 2020
  end-page: 979
  ident: CR25
  article-title: Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy
  publication-title: Cell Res
– year: 2021
  ident: CR129
  article-title: Overcoming PD-1 blockade resistance with CpG-A toll-like receptor 9 agonist vidutolimod in patients with metastatic melanoma
  publication-title: Cancer Discov
  doi: 10.1158/2159-8290
– volume: 5
  start-page: e1214790
  year: 2016
  ident: CR145
  article-title: Trial watch: immunotherapy plus radiation therapy for oncological indications
  publication-title: Oncoimmunology
– volume: 9
  start-page: 1796002
  year: 2020
  ident: CR76
  article-title: Trial watch: experimental TLR7/TLR8 agonists for oncological indications
  publication-title: Oncoimmunology
– volume: 6
  start-page: 226ra232
  year: 2014
  ident: CR102
  article-title: Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy
  publication-title: Sci Transl Med
– volume: 18
  start-page: 219
  year: 2019
  end-page: 234
  ident: CR11
  article-title: Interferons alpha and beta in cancer: therapeutic opportunities from new insights
  publication-title: Nat Rev Drug Discov
– volume: 29
  start-page: 611
  year: 2021
  end-page: 625
  ident: CR104
  article-title: First-in-human phase I clinical trial of an SFV-based RNA replicon cancer vaccine against HPV-induced cancers
  publication-title: Mol Ther
– volume: 33
  start-page: 2780
  year: 2015
  end-page: 2788
  ident: CR152
  article-title: Talimogene laherparepvec improves durable response rate in patients with advanced melanoma
  publication-title: J Clin Oncol
– volume: 30
  start-page: v557
  year: 2018
  ident: CR141
  article-title: LBA15Preliminary results of the first-in-human (FIH) study of MK-1454, an agonist of stimulator of interferon genes (STING), as monotherapy or in combination with pembrolizumab (pembro) in patients with advanced solid tumors or lymphomas
  publication-title: Ann Oncol
– volume: 53
  start-page: 43
  year: 2020
  end-page: 53
  ident: CR22
  article-title: Structures and mechanisms in the cGAS-STING innate immunity pathway
  publication-title: Immunity
– volume: 3
  start-page: 1362
  year: 1989
  end-page: 1371
  ident: CR12
  article-title: Cytoplasmic activation of ISGF3, the positive regulator of interferon-alpha-stimulated transcription, reconstituted in vitro
  publication-title: Genes Dev
– volume: 379
  start-page: 150
  year: 2018
  end-page: 161
  ident: CR100
  article-title: Recurrent glioblastoma treated with recombinant poliovirus
  publication-title: N Engl J Med
– volume: 6
  start-page: B43
  year: 2018
  ident: CR90
  article-title: Abstract B43: Novel small-molecule human STING agonists generate robust Type I interferon responses in tumors
  publication-title: Cancer Immunol Res
– volume: 75
  start-page: 497
  year: 2015
  end-page: 507
  ident: CR103
  article-title: Strict requirement for vector-induced type I interferon in efficacious antitumor responses to virally encoded IL12
  publication-title: Cancer Res
– volume: 30
  start-page: 1065
  year: 2020
  end-page: 1070
  ident: CR147
  article-title: CALLA: Efficacy and safety of concurrent and adjuvant durvalumab with chemoradiotherapy versus chemoradiotherapy alone in women with locally advanced cervical cancer: a phase III, randomized, double-blind, multicenter study
  publication-title: Int J Gynecol Cancer
– volume: 48
  start-page: 675
  year: 2018
  end-page: 687
  ident: CR24
  article-title: Manganese increases the sensitivity of the cGAS-STING pathway for double-stranded DNA and Is required for the host defense against DNA viruses
  publication-title: Immunity
– volume: 22
  start-page: 758
  year: 2020
  end-page: 766
  ident: CR42
  article-title: STING and IRF3 in stromal fibroblasts enable sensing of genomic stress in cancer cells to undermine oncolytic viral therapy
  publication-title: Nat Cell Biol
– volume: 30
  start-page: v533
  year: 2019
  end-page: v563
  ident: CR159
  article-title: Final results from phase II of combination with canerpaturev (formerly HF10), an oncolytic viral immunotherapy, and ipilimumab in unresectable or metastatic melanoma in second-or later line treatment
  publication-title: Ann Oncol
– volume: 4
  start-page: 497
  year: 2021
  ident: CR89
  article-title: ExoSTING, an extracellular vesicle loaded with STING agonists, promotes tumor immune surveillance
  publication-title: Commun Biol
– volume: 6
  start-page: 6
  year: 2016
  ident: CR98
  article-title: First oncolytic viral therapy for melanoma
  publication-title: Cancer Discov
– volume: 9
  start-page: 244
  year: 2005
  end-page: 254
  ident: CR6
  article-title: IFN-zeta/ limitin: a member of type I IFN with mild lympho-myelosuppression
  publication-title: J Cell Mol Med
– volume: 75
  start-page: 4483
  year: 2015
  end-page: 4493
  ident: CR64
  article-title: Suppression of Intratumoral CCL22 by type I Interferon inhibits migration of regulatory T cells and blocks cancer progression
  publication-title: Can Res
– volume: 34
  start-page: 2619
  year: 2016
  end-page: 2626
  ident: CR153
  article-title: Talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma
  publication-title: J Clin Oncol
– volume: 9
  start-page: e002195
  year: 2021
  ident: CR139
  article-title: STING activation normalizes the intraperitoneal vascular-immune microenvironment and suppresses peritoneal carcinomatosis of colon cancer
  publication-title: J Immunother Cancer
– volume: 8
  start-page: e1532763
  year: 2019
  ident: CR160
  article-title: Combination of immunogenic oncolytic adenovirus ONCOS-102 with anti-PD-1 pembrolizumab exhibits synergistic antitumor effect in humanized A2058 melanoma huNOG mouse model
  publication-title: Oncoimmunology
– volume: 49
  start-page: 754
  year: 2018
  end-page: 763
  ident: CR50
  article-title: Tumor-derived cGAMP triggers a STING-mediated interferon response in non-tumor cells to activate the NK cell response
  publication-title: Immunity
– volume: 21
  start-page: 532
  year: 2014
  end-page: 541
  ident: CR62
  article-title: Type I IFN gene delivery suppresses regulatory T cells within tumors
  publication-title: Cancer Gene Ther
– volume: 77
  start-page: CT026
  year: 2017
  ident: CR163
  article-title: Abstract CT026: Phase 1b study of intratumoral Coxsackievirus A21 (CVA21) and systemic pembrolizumab in advanced melanoma patients: Interim results of the CAPRA clinical trial
  publication-title: Cancer Res
– volume: 12
  start-page: 1858
  year: 2021
  ident: CR101
  article-title: Viral infection of cells within the tumor microenvironment mediates antitumor immunotherapy via selective TBK1-IRF3 signaling
  publication-title: Nat Commun
– volume: 124
  start-page: 1110
  year: 2021
  end-page: 1120
  ident: CR44
  article-title: Inhibition of interferon-signalling halts cancer-associated fibroblast-dependent protection of breast cancer cells from chemotherapy
  publication-title: Br J Cancer
– volume: 29
  start-page: 846
  year: 2019
  end-page: 861
  ident: CR114
  article-title: Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade
  publication-title: Cell Res
– volume: 8
  start-page: e000940
  year: 2020
  ident: CR128
  article-title: In situ immunization of a TLR9 agonist virus-like particle enhances anti-PD1 therapy
  publication-title: J Immunother Cancer
– volume: 28
  start-page: 4324
  year: 2010
  end-page: 4332
  ident: CR82
  article-title: In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study
  publication-title: J Clin Oncol
– volume: 14
  start-page: 7200
  year: 2020
  end-page: 7215
  ident: CR80
  article-title: Pulmonary delivery of nanoparticle-bound toll-like receptor 9 agonist for the treatment of metastatic lung cancer
  publication-title: ACS Nano
– volume: 4
  start-page: 51
  year: 2016
  ident: CR144
  article-title: Current clinical trials testing the combination of immunotherapy with radiotherapy
  publication-title: J Immunother Cancer
– volume: 503
  start-page: 530
  year: 2013
  end-page: 534
  ident: CR36
  article-title: Cell intrinsic immunity spreads to bystander cells via the intercellular transfer of cGAMP
  publication-title: Nature
– volume: 7
  start-page: e2191
  year: 2016
  ident: CR43
  article-title: Activated human mesenchymal stem/stromal cells suppress metastatic features of MDA-MB-231 cells by secreting IFN-beta
  publication-title: Cell Death Dis
– volume: 8
  start-page: 1250
  year: 2018
  end-page: 1257
  ident: CR126
  article-title: SD-101 in Combination with pembrolizumab in advanced melanoma: results of a phase Ib, multicenter study
  publication-title: Cancer Discov
– volume: 126
  start-page: 2404
  year: 2016
  end-page: 2411
  ident: CR23
  article-title: The host STING pathway at the interface of cancer and immunity
  publication-title: J Clin Invest
– volume: 191
  start-page: 3509
  year: 2013
  end-page: 3513
  ident: CR71
  article-title: Cutting edge: DNA sensing via the STING adaptor in myeloid dendritic cells induces potent tolerogenic responses
  publication-title: J Immunol
– volume: 139
  start-page: 1350
  year: 2016
  ident: 4219_CR17
  publication-title: Int J Cancer
  doi: 10.1002/ijc.30159
– volume: 134
  start-page: 1346
  year: 2014
  ident: 4219_CR56
  publication-title: Int J Cancer
  doi: 10.1002/ijc.28551
– volume: 49
  start-page: 754
  year: 2018
  ident: 4219_CR50
  publication-title: Immunity
  doi: 10.1016/j.immuni.2018.09.016
– volume: 108
  start-page: 7142
  year: 2011
  ident: 4219_CR92
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.1016569108
– year: 2021
  ident: 4219_CR129
  publication-title: Cancer Discov
  doi: 10.1158/2159-8290
– volume: 147
  start-page: 268
  year: 1957
  ident: 4219_CR2
  publication-title: Proc R Soc Lond B Biol Sci
  doi: 10.1098/rspb.1957.0049
– volume: 3
  start-page: e29179
  year: 2014
  ident: 4219_CR75
  publication-title: Oncoimmunology
  doi: 10.4161/onci.29179
– volume: 8
  start-page: 1258
  year: 2018
  ident: 4219_CR97
  publication-title: Cancer Discov
  doi: 10.1158/2159-8290.CD-18-0743
– volume: 151
  start-page: 375
  year: 2021
  ident: 4219_CR150
  publication-title: J Neurooncol
  doi: 10.1007/s11060-020-03481-0
– volume: 9
  start-page: 244
  year: 2005
  ident: 4219_CR6
  publication-title: J Cell Mol Med
  doi: 10.1111/j.1582-4934.2005.tb00353.x
– volume: 28
  start-page: 4324
  year: 2010
  ident: 4219_CR82
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2010.28.9793
– volume: 11
  start-page: 1018
  year: 2015
  ident: 4219_CR40
  publication-title: Cell Rep
  doi: 10.1016/j.celrep.2015.04.031
– volume: 73
  start-page: 5647
  year: 2013
  ident: 4219_CR63
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-12-3788
– volume: 30
  start-page: e1803397
  year: 2018
  ident: 4219_CR78
  publication-title: Adv Mater
  doi: 10.1002/adma.201803397
– volume: 35
  start-page: 9510
  year: 2017
  ident: 4219_CR158
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2017.35.15_suppl.9510
– volume: 4
  start-page: 1753
  year: 1990
  ident: 4219_CR13
  publication-title: Genes Dev
  doi: 10.1101/gad.4.10.1753
– volume: 126
  start-page: 2404
  year: 2016
  ident: 4219_CR23
  publication-title: J Clin Invest
  doi: 10.1172/JCI86892
– volume: 7
  start-page: 116
  year: 2019
  ident: 4219_CR118
  publication-title: J Immunother Cancer
  doi: 10.1186/s40425-019-0568-2
– volume: 29
  start-page: 2965
  year: 2011
  ident: 4219_CR86
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2011.35.0660
– volume: 9
  start-page: 1777624
  year: 2020
  ident: 4219_CR87
  publication-title: Oncoimmunology
  doi: 10.1080/2162402X.2020.1777624
– volume: 30
  start-page: 966
  year: 2020
  ident: 4219_CR25
  publication-title: Cell Res
  doi: 10.1038/s41422-020-00395-4
– volume: 208
  start-page: 2005
  year: 2011
  ident: 4219_CR19
  publication-title: J Exp Med
  doi: 10.1084/jem.20101159
– volume: 153
  start-page: 1094
  year: 2013
  ident: 4219_CR21
  publication-title: Cell
  doi: 10.1016/j.cell.2013.04.046
– volume: 6
  start-page: B43
  year: 2018
  ident: 4219_CR90
  publication-title: Cancer Immunol Res
  doi: 10.1158/2326-6074.TUMIMM17-B43
– volume: 13
  start-page: 1050
  year: 2007
  ident: 4219_CR26
  publication-title: Nat Med
  doi: 10.1038/nm1622
– volume: 37
  start-page: 2507
  year: 2019
  ident: 4219_CR140
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2019.37.15_suppl.2507
– volume: 147
  start-page: 258
  year: 1957
  ident: 4219_CR1
  publication-title: Proc R Soc Lond B Biol Sci
  doi: 10.1098/rspb.1957.0048
– volume: 58
  start-page: 1004
  year: 1967
  ident: 4219_CR69
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.58.3.1004
– volume: 16
  start-page: 749
  year: 2009
  ident: 4219_CR39
  publication-title: Cell Death Differ
  doi: 10.1038/cdd.2009.7
– volume: 15
  start-page: 405
  year: 2015
  ident: 4219_CR72
  publication-title: Nat Rev Immunol
  doi: 10.1038/nri3845
– volume: 12
  start-page: 2626
  year: 2021
  ident: 4219_CR106
  publication-title: Nat Commun
  doi: 10.1038/s41467-021-22929-z
– volume: 113
  start-page: E7240
  year: 2016
  ident: 4219_CR125
  publication-title: Proc Natl Acad Sci U S A
– volume: 29
  start-page: 611
  year: 2021
  ident: 4219_CR104
  publication-title: Mol Ther
  doi: 10.1016/j.ymthe.2020.11.002
– volume: 18
  start-page: 219
  year: 2019
  ident: 4219_CR11
  publication-title: Nat Rev Drug Discov
  doi: 10.1038/s41573-018-0011-2
– volume: 9
  start-page: 1796002
  year: 2020
  ident: 4219_CR76
  publication-title: Oncoimmunology
  doi: 10.1080/2162402X.2020.1796002
– volume: 29
  start-page: 162
  year: 2019
  ident: 4219_CR111
  publication-title: Cell Rep
  doi: 10.1016/j.celrep.2019.08.086
– volume: 25
  start-page: 3074
  year: 2018
  ident: 4219_CR138
  publication-title: Cell Rep
  doi: 10.1016/j.celrep.2018.11.047
– volume: 52
  start-page: 125
  year: 2018
  ident: 4219_CR143
  publication-title: Semin Cancer Biol
  doi: 10.1016/j.semcancer.2017.12.007
– volume: 50
  start-page: 907
  year: 2019
  ident: 4219_CR7
  publication-title: Immunity
  doi: 10.1016/j.immuni.2019.03.025
– volume: 33
  start-page: 2780
  year: 2015
  ident: 4219_CR152
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2014.58.3377
– volume: 458
  start-page: 899
  year: 2009
  ident: 4219_CR28
  publication-title: Nature
  doi: 10.1038/nature07750
– volume: 9
  start-page: 411
  year: 2018
  ident: 4219_CR115
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2018.00411
– volume: 78
  start-page: 5554
  year: 2018
  ident: 4219_CR91
  publication-title: Cancer Res
  doi: 10.1158/1538-7445.AM2018-5554
– volume: 397
  start-page: 1010
  year: 2021
  ident: 4219_CR113
  publication-title: The Lancet
  doi: 10.1016/S0140-6736(20)32598-8
– volume: 20
  start-page: 485
  year: 2020
  ident: 4219_CR54
  publication-title: Nat Rev Cancer
  doi: 10.1038/s41568-020-0281-y
– volume: 4
  start-page: e1900237
  year: 2020
  ident: 4219_CR46
  publication-title: Adv Biosyst
  doi: 10.1002/adbi.201900237
– volume: 39
  start-page: 394
  year: 2021
  ident: 4219_CR99
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2020.12.022
– volume: 548
  start-page: 466
  year: 2017
  ident: 4219_CR137
  publication-title: Nature
  doi: 10.1038/nature23470
– volume: 77
  start-page: CT026
  year: 2017
  ident: 4219_CR163
  publication-title: Cancer Res
  doi: 10.1158/1538-7445.AM2017-CT026
– volume: 129
  start-page: 518
  year: 2019
  ident: 4219_CR108
  publication-title: J Clin Invest
  doi: 10.1172/JCI121004
– volume: 175
  start-page: 113803
  year: 2021
  ident: 4219_CR119
  publication-title: Adv Drug Deliv Rev
  doi: 10.1016/j.addr.2021.05.013
– volume: 32
  start-page: S867
  year: 2021
  ident: 4219_CR161
  publication-title: Ann Oncol
  doi: 10.1016/j.annonc.2021.08.1421
– volume: 51
  start-page: 146
  year: 2015
  ident: 4219_CR131
  publication-title: Eur J Cancer
  doi: 10.1016/j.ejca.2014.11.002
– volume: 74
  start-page: 2986
  year: 2014
  ident: 4219_CR41
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-13-2689
– volume: 168
  start-page: 707
  year: 2017
  ident: 4219_CR112
  publication-title: Cell
  doi: 10.1016/j.cell.2017.01.017
– volume: 25
  start-page: 37
  year: 2014
  ident: 4219_CR93
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2013.12.004
– volume: 53
  start-page: 43
  year: 2020
  ident: 4219_CR22
  publication-title: Immunity
  doi: 10.1016/j.immuni.2020.05.013
– volume: 137
  start-page: 837
  year: 2015
  ident: 4219_CR59
  publication-title: Int J Cancer
  doi: 10.1002/ijc.29444
– volume: 5
  start-page: e1214790
  year: 2016
  ident: 4219_CR145
  publication-title: Oncoimmunology
  doi: 10.1080/2162402X.2016.1214790
– volume: 36
  start-page: 503
  year: 2012
  ident: 4219_CR10
  publication-title: Immunity
  doi: 10.1016/j.immuni.2012.03.013
– volume: 38
  start-page: 400
  year: 2020
  ident: 4219_CR165
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2020.05.020
– volume: 7
  start-page: 113
  year: 2019
  ident: 4219_CR48
  publication-title: J Immunother Cancer
  doi: 10.1186/s40425-019-0552-x
– volume: 29
  start-page: 846
  year: 2019
  ident: 4219_CR114
  publication-title: Cell Res
  doi: 10.1038/s41422-019-0224-x
– volume: 4
  start-page: 51
  year: 2016
  ident: 4219_CR144
  publication-title: J Immunother Cancer
  doi: 10.1186/s40425-016-0156-7
– volume: 348
  start-page: 217
  year: 2019
  ident: 4219_CR4
  publication-title: Int Rev Cell Mol Biol
  doi: 10.1016/bs.ircmb.2019.06.001
– volume: 202
  start-page: 8
  year: 2004
  ident: 4219_CR5
  publication-title: Immunol Rev
  doi: 10.1111/j.0105-2896.2004.00204.x
– volume: 122
  start-page: 575
  year: 2012
  ident: 4219_CR73
  publication-title: J Clin Invest
  doi: 10.1172/JCI61034
– volume: 77
  start-page: CT114
  year: 2017
  ident: 4219_CR162
  publication-title: Cancer Res
  doi: 10.1158/1538-7445.AM2017-CT114
– volume: 61
  start-page: 195
  year: 2009
  ident: 4219_CR81
  publication-title: Adv Drug Deliv Rev
  doi: 10.1016/j.addr.2008.12.008
– volume: 11
  start-page: 2739
  year: 2020
  ident: 4219_CR142
  publication-title: Nat Commun
  doi: 10.1038/s41467-020-16602-0
– volume: 7
  start-page: e2191
  year: 2016
  ident: 4219_CR43
  publication-title: Cell Death Dis
  doi: 10.1038/cddis.2016.90
– volume: 170
  start-page: 1109
  year: 2017
  ident: 4219_CR154
  publication-title: Cell
  doi: 10.1016/j.cell.2017.08.027
– volume: 5
  start-page: 871
  year: 2017
  ident: 4219_CR117
  publication-title: Cancer Immunol Res
  doi: 10.1158/2326-6066.CIR-17-0150
– volume: 234
  start-page: 7051
  year: 2019
  ident: 4219_CR31
  publication-title: J Cell Physiol
  doi: 10.1002/jcp.27459
– volume: 178
  start-page: 7540
  year: 2007
  ident: 4219_CR49
  publication-title: J Immunol
  doi: 10.4049/jimmunol.178.12.7540
– volume: 26
  start-page: 5153
  year: 2020
  ident: 4219_CR156
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-20-1170
– volume: 32
  start-page: 6082
  year: 2014
  ident: 4219_CR157
  publication-title: J Clin Oncol
  doi: 10.1200/jco.2014.32.15_suppl.6082
– volume: 379
  start-page: 150
  year: 2018
  ident: 4219_CR100
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1716435
– volume: 41
  start-page: 830
  year: 2014
  ident: 4219_CR18
  publication-title: Immunity
  doi: 10.1016/j.immuni.2014.10.017
– volume: 136
  start-page: 572
  year: 2015
  ident: 4219_CR55
  publication-title: Int J Cancer
  doi: 10.1002/ijc.28957
– volume: 17
  start-page: 2619
  year: 2011
  ident: 4219_CR9
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-10-1114
– volume: 39
  start-page: 2512
  year: 2021
  ident: 4219_CR121
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2021.39.15_suppl.2512
– volume: 5
  start-page: 375
  year: 2005
  ident: 4219_CR8
  publication-title: Nat Rev Immunol
  doi: 10.1038/nri1604
– volume: 31
  start-page: S736
  year: 2020
  ident: 4219_CR123
  publication-title: Ann Oncol
  doi: 10.1016/j.annonc.2020.08.1207
– volume: 20
  start-page: 1670
  year: 2019
  ident: 4219_CR146
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(19)30519-4
– volume: 131
  start-page: e141614
  year: 2021
  ident: 4219_CR164
  publication-title: J Clin Invest
  doi: 10.1172/JCI141614
– volume: 43
  start-page: 101299
  year: 2019
  ident: 4219_CR15
  publication-title: Semin Immunol
  doi: 10.1016/j.smim.2019.101299
– volume: 75
  start-page: 497
  year: 2015
  ident: 4219_CR103
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-13-3356
– volume: 48
  start-page: 675
  year: 2018
  ident: 4219_CR24
  publication-title: Immunity
  doi: 10.1016/j.immuni.2018.03.017
– volume: 20
  start-page: 1301
  year: 2014
  ident: 4219_CR32
  publication-title: Nat Med
  doi: 10.1038/nm.3708
– volume: 39
  start-page: 1388
  year: 2021
  ident: 4219_CR151
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2021.08.008
– volume: 4
  start-page: 674
  year: 2014
  ident: 4219_CR116
  publication-title: Cancer Discov
  doi: 10.1158/2159-8290.CD-13-0458
– volume: 8
  start-page: A199
  year: 2020
  ident: 4219_CR120
  publication-title: J Immunother Cancer
  doi: 10.1136/jitc-2020-001198
– volume: 124
  start-page: 1110
  year: 2021
  ident: 4219_CR44
  publication-title: Br J Cancer
  doi: 10.1038/s41416-020-01226-4
– volume: 2
  start-page: 44ra57
  year: 2010
  ident: 4219_CR29
  publication-title: Sci Transl Med
  doi: 10.1126/scitranslmed.3000739
– volume: 20
  start-page: 1062
  year: 2013
  ident: 4219_CR52
  publication-title: Gene Ther
  doi: 10.1038/gt.2013.31
– volume: 8
  start-page: e1532763
  year: 2019
  ident: 4219_CR160
  publication-title: Oncoimmunology
  doi: 10.1080/2162402X.2018.1532763
– volume: 138
  start-page: 1982
  year: 2016
  ident: 4219_CR57
  publication-title: Int J Cancer
  doi: 10.1002/ijc.29945
– volume: 21
  start-page: 532
  year: 2014
  ident: 4219_CR62
  publication-title: Cancer Gene Ther
  doi: 10.1038/cgt.2014.60
– volume: 8
  start-page: 15618
  year: 2017
  ident: 4219_CR35
  publication-title: Nat Commun
  doi: 10.1038/ncomms15618
– volume: 30
  start-page: v557
  year: 2018
  ident: 4219_CR141
  publication-title: Ann Oncol
– volume: 3
  start-page: 1362
  year: 1989
  ident: 4219_CR12
  publication-title: Genes Dev
  doi: 10.1101/gad.3.9.1362
– volume: 63
  start-page: 51
  year: 1969
  ident: 4219_CR45
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.63.1.51
– volume: 15
  start-page: 471
  year: 2015
  ident: 4219_CR16
  publication-title: Nat Rev Immunol
  doi: 10.1038/nri3865
– volume: 3
  start-page: e120638
  year: 2018
  ident: 4219_CR88
  publication-title: JCI Insight
  doi: 10.1172/jci.insight.120638
– volume: 30
  start-page: v533
  year: 2019
  ident: 4219_CR159
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdz255
– volume: 72
  start-page: 592
  year: 2012
  ident: 4219_CR33
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-11-0534
– volume: 8
  start-page: e000940
  year: 2020
  ident: 4219_CR128
  publication-title: J Immunother Cancer
  doi: 10.1136/jitc-2020-000940
– volume: 11
  start-page: 3187
  year: 2020
  ident: 4219_CR109
  publication-title: Nat Commun
  doi: 10.1038/s41467-020-17011-z
– volume: 71
  start-page: 2488
  year: 2011
  ident: 4219_CR95
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-10-2820
– volume: 7
  start-page: 283ra252
  year: 2015
  ident: 4219_CR135
  publication-title: Sci Transl Med
– volume: 41
  start-page: 843
  year: 2014
  ident: 4219_CR34
  publication-title: Immunity
  doi: 10.1016/j.immuni.2014.10.019
– volume: 8
  start-page: 304
  year: 2017
  ident: 4219_CR51
  publication-title: Front Immunol
– volume: 9
  start-page: e002195
  year: 2021
  ident: 4219_CR139
  publication-title: J Immunother Cancer
  doi: 10.1136/jitc-2020-002195
– volume: 6
  start-page: 6
  year: 2016
  ident: 4219_CR98
  publication-title: Cancer Discov
– volume: 218
  start-page: e20200844
  year: 2021
  ident: 4219_CR85
  publication-title: J Exp Med
  doi: 10.1084/jem.20200844
– volume: 6
  start-page: 226ra232
  year: 2014
  ident: 4219_CR102
  publication-title: Sci Transl Med
  doi: 10.1126/scitranslmed.3008095
– volume: 191
  start-page: 3509
  year: 2013
  ident: 4219_CR71
  publication-title: J Immunol
  doi: 10.4049/jimmunol.1301419
– volume: 39
  start-page: e104036
  year: 2020
  ident: 4219_CR96
  publication-title: EMBO J
  doi: 10.15252/embj.2019104036
– volume: 30
  start-page: 1065
  year: 2020
  ident: 4219_CR147
  publication-title: Int J Gynecol Cancer
  doi: 10.1136/ijgc-2019-001135
– volume: 449
  start-page: 564
  year: 2007
  ident: 4219_CR27
  publication-title: Nature
  doi: 10.1038/nature06116
– volume: 15
  start-page: 700
  year: 2014
  ident: 4219_CR149
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(14)70189-5
– volume: 112
  start-page: 15408
  year: 2015
  ident: 4219_CR37
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.1512832112
– volume: 339
  start-page: 826
  year: 2013
  ident: 4219_CR20
  publication-title: Science
  doi: 10.1126/science.1229963
– volume: 7
  start-page: 323
  year: 2019
  ident: 4219_CR134
  publication-title: J Immunother Cancer
  doi: 10.1186/s40425-019-0811-x
– volume: 94
  start-page: 227
  year: 2015
  ident: 4219_CR53
  publication-title: Eur J Haematol
  doi: 10.1111/ejh.12420
– volume: 573
  start-page: 434
  year: 2019
  ident: 4219_CR30
  publication-title: Nature
  doi: 10.1038/s41586-019-1553-0
– volume: 8
  start-page: A185
  year: 2020
  ident: 4219_CR130
  publication-title: J Immunother Cancer
– volume: 120
  start-page: 1151
  year: 2010
  ident: 4219_CR58
  publication-title: J Clin Invest
  doi: 10.1172/JCI37223
– volume: 12
  start-page: 4558
  year: 2021
  ident: 4219_CR84
  publication-title: Nat Commun
  doi: 10.1038/s41467-021-24867-2
– volume: 72
  start-page: 5188
  year: 2012
  ident: 4219_CR66
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-11-3468
– volume: 8
  start-page: 1250
  year: 2018
  ident: 4219_CR126
  publication-title: Cancer Discov
  doi: 10.1158/2159-8290.CD-18-0280
– volume: 34
  start-page: 9568
  year: 2016
  ident: 4219_CR155
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2016.34.15_suppl.9568
– volume: 6
  start-page: 4
  year: 2021
  ident: 4219_CR70
  publication-title: Signal Transduct Target Ther
  doi: 10.1038/s41392-020-00377-3
– volume: 26
  start-page: 334
  year: 2019
  ident: 4219_CR65
  publication-title: Cancer Gene Ther
  doi: 10.1038/s41417-018-0059-5
– volume: 8
  start-page: e1659096
  year: 2019
  ident: 4219_CR133
  publication-title: Oncoimmunology
  doi: 10.1080/2162402X.2019.1659096
– volume: 7
  start-page: 629
  year: 2016
  ident: 4219_CR60
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2016.00629
– volume: 5
  start-page: 423
  year: 2005
  ident: 4219_CR83
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc1628
– volume: 21
  start-page: 511
  year: 2019
  ident: 4219_CR94
  publication-title: Nat Cell Biol
  doi: 10.1038/s41556-019-0298-1
– volume: 7
  start-page: e1526250
  year: 2018
  ident: 4219_CR127
  publication-title: Oncoimmunology
  doi: 10.1080/2162402X.2018.1526250
– volume: 16
  start-page: 202
  year: 2015
  ident: 4219_CR38
  publication-title: EMBO Rep
  doi: 10.15252/embr.201439366
– volume: 21
  start-page: e84
  year: 2020
  ident: 4219_CR148
  publication-title: Clin Lung Cancer
  doi: 10.1016/j.cllc.2019.12.006
– volume: 10
  start-page: eaao1641
  year: 2018
  ident: 4219_CR105
  publication-title: Sci Transl Med
  doi: 10.1126/scitranslmed.aao1641
– volume: 22
  start-page: 56
  year: 2018
  ident: 4219_CR74
  publication-title: Contemp Oncol (Pozn)
– volume: 13
  start-page: 12671
  year: 2019
  ident: 4219_CR79
  publication-title: ACS Nano
  doi: 10.1021/acsnano.9b04207
– volume: 34
  start-page: 2619
  year: 2016
  ident: 4219_CR153
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2016.67.1529
– volume: 77
  start-page: 4146
  year: 2017
  ident: 4219_CR110
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-16-2165
– volume: 75
  start-page: 4483
  year: 2015
  ident: 4219_CR64
  publication-title: Can Res
  doi: 10.1158/0008-5472.CAN-14-3499
– volume: 16
  start-page: 131
  year: 2016
  ident: 4219_CR3
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc.2016.14
– volume: 10
  start-page: 2921
  year: 2019
  ident: 4219_CR14
  publication-title: Nat Commun
  doi: 10.1038/s41467-019-10970-y
– volume: 114
  start-page: 1637
  year: 2017
  ident: 4219_CR136
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.1621363114
– volume: 129
  start-page: 4224
  year: 2019
  ident: 4219_CR47
  publication-title: J Clin Investig
  doi: 10.1172/JCI127458
– volume: 10
  start-page: 4eaan488
  year: 2018
  ident: 4219_CR77
  publication-title: Sci Transl Med
  doi: 10.1126/scitranslmed.aan4488
– volume: 4
  start-page: 497
  year: 2021
  ident: 4219_CR89
  publication-title: Commun Biol
  doi: 10.1038/s42003-021-02004-5
– volume: 71
  start-page: 521
  year: 2021
  ident: 4219_CR166
  publication-title: Gut
  doi: 10.1136/gutjnl-2020-323426
– volume: 6
  start-page: 362
  year: 2021
  ident: 4219_CR67
  publication-title: Signal Transduct Target Ther
  doi: 10.1038/s41392-021-00670-9
– volume: 12
  start-page: 1858
  year: 2021
  ident: 4219_CR101
  publication-title: Nat Commun
  doi: 10.1038/s41467-021-22088-1
– volume: 17
  start-page: 1765
  year: 2011
  ident: 4219_CR68
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-10-2672
– volume: 37
  start-page: TPS9599
  year: 2019
  ident: 4219_CR124
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2019.37.15_suppl.TPS9599
– volume: 29
  start-page: 2076
  year: 2018
  ident: 4219_CR132
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdy326
– volume: 22
  start-page: 758
  year: 2020
  ident: 4219_CR42
  publication-title: Nat Cell Biol
  doi: 10.1038/s41556-020-0527-7
– volume: 17
  start-page: 823
  year: 2018
  ident: 4219_CR61
  publication-title: Nat Rev Drug Discov
  doi: 10.1038/nrd.2018.148
– volume: 39
  start-page: 2549
  year: 2021
  ident: 4219_CR122
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2021.39.15_suppl.2549
– volume: 14
  start-page: 7200
  year: 2020
  ident: 4219_CR80
  publication-title: ACS Nano
  doi: 10.1021/acsnano.0c02207
– volume: 128
  start-page: 1413
  year: 2018
  ident: 4219_CR107
  publication-title: J Clin Invest
  doi: 10.1172/JCI98047
– volume: 503
  start-page: 530
  year: 2013
  ident: 4219_CR36
  publication-title: Nature
  doi: 10.1038/nature12640
SSID ssj0015826
Score 2.6873364
SecondaryResourceType review_article
Snippet Immune checkpoint blockade (ICB) therapies have achieved remarkable clinical responses in patients with many different types of cancer; however, most patients...
SourceID unpaywall
pubmedcentral
proquest
pubmed
crossref
springer
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 191
SubjectTerms Animals
Anticancer properties
Biochemistry
Biomedical and Life Sciences
Biomedicine
Cancer-Associated Fibroblasts - immunology
Cell Biology
Clinical trials
Combined Modality Therapy
Dendritic Cells - immunology
Endothelial Cells - immunology
Humans
Immune checkpoint
Immune Checkpoint Inhibitors - therapeutic use
Immune system
Immunity
Immunoregulation
Immunotherapy
Immunotherapy - methods
Interferon
Interferon Type I - biosynthesis
Interferon Type I - immunology
Killer Cells, Natural - immunology
Life Sciences
Lymphocytes, Tumor-Infiltrating - immunology
Macrophages - immunology
Mice
Models, Immunological
Myeloid-Derived Suppressor Cells - immunology
neoplasms
Neoplasms - immunology
Neoplasms - therapy
Neutrophils - immunology
Oncolytic Virotherapy
Patients
Review
Signal Transduction - immunology
synergism
Synergistic effect
T-Lymphocytes, Regulatory - immunology
Toll-Like Receptors - agonists
Tumor microenvironment
Tumor Microenvironment - immunology
Tumors
SummonAdditionalLinks – databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3daxQxEB-0IrYPYuvXtlUi-KDYYJPbbJInEbFWQZ8s3NuSzQc9OHevd3vI9a_vZDe39Sgcvm5mIZv5ZfKbzXwAvNVFhQcRL6hwIdBcCEeN5YY67QvJrQyqije6P38V5xf5j7EYpx9uixRWubaJnaF2jY3_yD9yPErRyqI_8Gl2RWPXqHi7mlpo3IcHDKlKRLUcDw4XE4r32UXRRVJ8nJJmutS5SG4UjbHsCFum6fXmwXSHbd4NmhxuTvfg0bKemdVfM53-czidPYHHiVWSzz0M9uGerw_gYd9ncnUA-2kHL8i7VGb6_VP4Fl1Q8p3EghHz4OdNTbs0EqSgpF3-aeZk0uWOtCtiakcm7YLEUESU7wdS6tbqGVycff395ZymtgrUCjlqqSm0dMHJivEgBQtWKKWDwUUorOPK2sLzYJVluZCOeW3VqEIzYArlT1014qPnsFM3tX8JhAmLjEur3LuQi1Oj8lBpwYN3yBzwcQZsvaalTTXHY-uLaTlUS-70UKIeyk4P5XUGH4Z3Zn3Fja3Sx2tVlWn3LcpbrGTwZhjGfRMvQ0ztm2WUidZL5rncKqNULBCIMi967Q9TQuKquVIsA7mBi0Eg1u3eHKknl139boU-L2Iyg5M1gm6nvu1LTwaU_cfCHG5fmCPY5R34YzTdMey086V_hfSqrV53e-gGVpsfdg
  priority: 102
  providerName: ProQuest
– databaseName: SpringerLINK - Czech Republic Consortium
  dbid: AGYKE
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwEB7BVgg4FFpeKQUZiQOIumq8cewcq6oPQHBipeUUOX6oK5ZstZsI7f56xokT2Bat6DWeRLbz2f5GM_MZ4G2WFngQsZRy4xxNODdUaaaoyWwqmBZOFj6i--VrejFKPo35OBSFLbps9y4k2ezUfbGbpyOS-uxzBFqc0dVd2OLeQRnA1vH598-nffSAS9ZWFXnXSLJxKJb591fWD6QbLPNmsmQfMX0I9-vySi1_qen0r0Pp7BGMuuG0uSg_DuuqONSra0qPtx3vY9gOLJUct7DagTu23IV77b2Vy13YCTvCgrwLstXvn8C5d2nJR-IFKObOzmclbcpSkNKSqv45m5NJU4tSLYkqDZlUC-JTG9G-bQilYMunMDo7_XZyQcM1DVRzMayoSjNhnBFFzJzgsdNcyswp7HKqDZNap5Y5LXWccGFim2k5LHBbUam0R6YYsuEzGJSz0r4AEnONDC6TiTUu4UdKJq7IOHPWIBPBxxHE3b_KddAw91dpTPNefbmZtRxnLW9mLV9F8KF_56pV8Nhovd9BIA-reZEzpHF4wqMvGsGbvhnXoQ-uqNLOam_jd0ORJGKjjZRecBBtnreo6ruERDhjUsYRiDW89QZeB3y9pZxcNnrgEn1oxHoEBx2Q_nR900gPevT-x8Ts3e7rL-EBa6Drs_X2YVDNa_sK6VtVvA6r9TehRzob
  priority: 102
  providerName: Springer Nature
Title Type I interferon-mediated tumor immunity and its role in immunotherapy
URI https://link.springer.com/article/10.1007/s00018-022-04219-z
https://www.ncbi.nlm.nih.gov/pubmed/35292881
https://www.proquest.com/docview/2639123140
https://www.proquest.com/docview/2640047447
https://www.proquest.com/docview/2648854437
https://pubmed.ncbi.nlm.nih.gov/PMC8924142
https://link.springer.com/content/pdf/10.1007/s00018-022-04219-z.pdf
UnpaywallVersion publishedVersion
Volume 79
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVLSH
  databaseName: SpringerLink Journals
  customDbUrl:
  mediaType: online
  eissn: 1420-9071
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0015826
  issn: 1420-9071
  databaseCode: AFBBN
  dateStart: 19970101
  isFulltext: true
  providerName: Library Specific Holdings
– providerCode: PRVAQN
  databaseName: PubMed Central
  customDbUrl:
  eissn: 1420-9071
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0015826
  issn: 1420-9071
  databaseCode: RPM
  dateStart: 19970101
  isFulltext: true
  titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/
  providerName: National Library of Medicine
– providerCode: PRVAVX
  databaseName: HAS SpringerNature Open Access 2022
  customDbUrl:
  eissn: 1420-9071
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0015826
  issn: 1420-9071
  databaseCode: AAJSJ
  dateStart: 19970101
  isFulltext: true
  titleUrlDefault: https://www.springernature.com
  providerName: Springer Nature
– providerCode: PRVAVX
  databaseName: SpringerLINK - Czech Republic Consortium
  customDbUrl:
  eissn: 1420-9071
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0015826
  issn: 1420-9071
  databaseCode: AGYKE
  dateStart: 19970101
  isFulltext: true
  titleUrlDefault: http://link.springer.com
  providerName: Springer Nature
– providerCode: PRVAVX
  databaseName: SpringerLink Journals (ICM)
  customDbUrl:
  eissn: 1420-9071
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0015826
  issn: 1420-9071
  databaseCode: U2A
  dateStart: 19970101
  isFulltext: true
  titleUrlDefault: http://www.springerlink.com/journals/
  providerName: Springer Nature
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwED9trRDwAGx8BUYVJB5ALN3ixrHzWEq3AaKaEJW6p8jxh6goadUmQu1fzzlfUIYqEC9JFF8i2znbv8vd_QzwIgoTXIhI6FFljBdQqjwhifBUpENGJDM8sR7dj6PwYhy8n9DJHrytc2GKaPfaJVnmNFiWpjQ7WShz0iS-WWjCPRuJjkrnR96mi8X70A6tm6kF7fHosn9VJBZZ64iTSX2NtqBf5c78-UXb69M10Hk9drJxoN6Gm3m6EOvvYjb7ZY06uwu6bl0ZmvK1m2dJV25-I3783-bfgzsViHX7pdYdwJ5OD-FGua3l-hAOqglj5b6sWK1f3Ydza_G671zLT7E0ejlPvSJrBRGvm-Xf5kt3WqSqZGtXpMqdZivXRj6ifFlQZYqtH8D4bPh5cOFVuzh4krJe5okwYsoolvjEMOobSTmPjMBqh1IRLmWoiZFc-gFlyteR5L0EZx0Rcn2qkh7pPYRWOk_1Y3B9KhHgRTzQygT0VPDAJBElRisEKnjbAb_-drGsKM7tThuzuCFnLnouxp6Li56LNw68bp5ZlAQfO6WPapWIq8G-igmiPAQAaKo68LwpxmFqfS8i1fPcytjJkgUB2ynDueUjRJlHpZY1VUKcHBHOfQfYlv41ApYmfLsknX4p6MI5mtio-w4c14r1s-q7WnrcaPNfdMyTfxN_CrdIob42mO8IWtky188Q3WVJB_bZhHWg3T-_-jDE85vh6PIT3h2Eg07xMw6PY9LvVIP8BwqbTGg
linkProvider Unpaywall
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEB5VRaj0gGh5GQosEkgguiLeeL3rA0IIKAl9nFopN3e9DxEpdULiqHJ_FL-RWb9KVCni0qt3LK13HjvjmfkG4E0SZ3gRsZhy4xyNODdUaaaoSWwsmBZOZj6je3wSD86inyM-2oA_bS-ML6tsbWJlqM1U-3_kHxlepWhlMR74PPtN_dQon11tR2jUYnFoy0sM2Rafht-Qv28ZO_h--nVAm6kCVHPRL6iKE2GcEVnInOCh01zKxCnU3FgbJrWOLXNa6jDiwoQ20bKfoRaoWNqeyfoe6ABN_p2o34s8Vr8YdQFeyCWru5l8SCbZqGnSqVr1vDMlqa-dRzUJE3q1ehHe8G5vFml2mdpt2FrmM1Veqsnkn8vw4AHcb7xY8qUWux3YsPku3K3nWpa7sNNYjAV518Bav38IP3zIS4bEA1TMnZ1Pc1q1raDLS4rlxXROxlWvSlESlRsyLhbElz4ifb3QtIqVj-DsVg78MWzm09w-BRJyjR5eIiNrXMR7SkYuSzhz1qCngo8DCNszTXWDce5HbUzSDp254kOKfEgrPqRXAXzo3pnVCB9rqfdaVqWNti_Sa9kM4HW3jHrqky8qt9Olp_HWUkSRWEsjpQckRJonNfe7LaGjnDApwwDEilx0BB4nfHUlH_-q8MIlxtgokwHstxJ0vfV1X7rfSdl_HMyz9QfzCrYGp8dH6dHw5PA53GOVIvhKvj3YLOZL-wJduyJ7WekTgfPbVuC_04dc-g
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEB5VRbwOiJaXocAigQRqV63XXu_6gBCihIZCxYFKuZn1PkSk4ITEUeX-NH4ds36VqFLEpdfsWLJ35pudyc58A_AyTXI8iFhCuXGOxpwbqjRT1KQ2EUwLJ3N_o_v1JDk6jT-P-GgD_nS9ML6ssvOJtaM2U-3_I99neJSil8V8YN-1ZRHfDgfvZr-pnyDlb1q7cRqNiRzb6gzTt8Xb4SHq-hVjg4_fPxzRdsIA1VxEJVVJKowzIg-ZEzx0mkuZOoUoTrRhUuvEMqelDmMuTGhTLaMcEaESaQ9MHnnSA3T_10QUR76cTIz6ZC_kkjWdTT49k2zUNuzUbXs-sJLU19EjZMKUnq8eipci3csFm_2t7W24uSxmqjpTk8k_B-PgLtxpI1ryvjHBLdiwxTZcb2ZcVtuw1XqPBXndUly_uQeffPpLhsSTVcydnU8LWrewYPhLyuWv6ZyM676VsiKqMGRcLogvg0T5ZqFtG6vuw-mVbPgD2CymhX0EJOQao71Uxta4mB8oGbs85cxZg1EL_hxA2O1pplu-cz92Y5L1TM21HjLUQ1brITsPYLd_ZtawfayV3ulUlbXIX2QXdhrAi34ZMesvYlRhp0sv4z2niGOxVkZKT06IMg8b7fevhEFzyqQMAxArdtELeM7w1ZVi_LPmDpeYb6NNBrDXWdDFq6_70r3eyv5jYx6v35jncAOhm30Znhw_gVusxoEv6tuBzXK-tE8xyivzZzWcCPy4avz-BWPJYTU
linkToUnpaywall http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3fb9MwED6NTojtAdhgEBjISDyAmLvFjWPncQLGQGLigUrlKXL8Q1Tr0qpNNLV_Pef8gjJUgXiL6mtkO5_t73R3nwFeJnGGBxGLKTfO0YhzQ5VmiprExoJp4WTmI7qfL-LzYfRpxEdb8K6thamy3duQZF3T4FWa8uJ4ZtxxV_jmqYmkPhMdQRcmdNXH5luwHfswUw-2hxdfTr9VhUXeO5Js1D6jLxg2tTN_ftH6-XSDdN7MnewCqLtwp8xnanmtJpNfzqize2Db0dWpKZf9ssj6evWb8OP_Dv8-3G1ILDmtUbcHWzbfh9v1tZbLfdhrNowFedWoWr9-AB-8x0s-Eq9PMXd2Ps1pVbWCjJcU5dV0TsZVqUqxJCo3ZFwsiM98RPu6oakUWz6E4dn7r2_PaXOLA9VcDAqq4kQYZ0QWMid46DSXMnEKux1rw6TWsWVOSx1GXJjQJloOMtx1VCztickGbHAAvXya28dAQq6R4CUyssZF_ETJyGUJZ84aJCr4cwBh--1S3Uic-5s2JmknzlzNXIozl1Yzl64CeNP9Z1YLfGy0PmwhkTaLfZEyZHlIANBVDeBF14zL1MdeVG6npbfxm6WIIrHRRkqvR4g2j2qUdV1CnpwwKcMAxBr-OgMvE77eko-_V3LhEl1sxH4ARy2wfnZ900iPOjT_xcQ8-Tfzp7DDKvj6ZL5D6BXz0j5Ddldkz5vF-wOxGUV9
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Type+I+interferon-mediated+tumor+immunity+and+its+role+in+immunotherapy&rft.jtitle=Cellular+and+molecular+life+sciences+%3A+CMLS&rft.au=Yu%2C+Renren&rft.au=Zhu%2C+Bo&rft.au=Chen%2C+Degao&rft.date=2022-03-01&rft.eissn=1420-9071&rft.volume=79&rft.issue=3&rft.spage=191&rft_id=info:doi/10.1007%2Fs00018-022-04219-z&rft_id=info%3Apmid%2F35292881&rft.externalDocID=35292881
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1420-682X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1420-682X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1420-682X&client=summon